Review

Resveratrol’s Anti-Cancer Effects through the Modulation of Tumor Glucose Metabolism

Aranka Brockmueller 1, Saba Sameri 2, Alena Liskova 3, Kevin Zhai 4*, Elizabeth Varghese 4, Samson Mathews Samuel 4*, Dietrich Büsselberg 4©, Peter Kubatka 5© and Mehdi Shakibaei 1,4©

1 Musculoskeletal Research Group and Tumor Biology, Chair of Vegetative Anatomy, Institute of Anatomy, Faculty of Medicine, Ludwig-Maximilian-University Munich, Pettenkoferstrasse 11, D-80336 Munich, Germany; Aranka.Brockmueller@med.uni-muenchen.de
2 Department of Molecular Medicine and Genetics, Hamadan University of Medical Sciences, 6517838678 Hamadan, Iran; saba.sameri93@gmail.com
3 Department of Obstetrics and Gynecology, Jessenius Faculty of Medicine, Comenius University in Bratislava, 036 01 Martin, Slovakia; liskova80@uniba.sk
4 Department of Physiology and Biophysics, Weill Cornell Medicine-Qatar, Education City, Qatar Foundation, Doha 24144, Qatar; kez4003@qatar-med.cornell.edu (K.Z.); elv2007@qatar-med.cornell.edu (E.V.); sms2016@qatar-med.cornell.edu (S.M.S.); dib2015@qatar-med.cornell.edu (D.B.)
5 Department of Medical Biology, Jessenius Faculty of Medicine, Comenius University in Bratislava, 036 01 Martin, Slovakia; peter.kubatka@uniba.sk
* Correspondence: mehdi.shakibaei@med.uni-muenchen.de; Tel.: +49-892-1807-2624; Fax: +49-892-1807-2625

Abstract: Tumor cells develop several metabolic reprogramming strategies, such as increased glucose uptake and utilization via aerobic glycolysis and fermentation of glucose to lactate; these lead to a low pH environment in which the cancer cells thrive and evade apoptosis. These characteristics of tumor cells are known as the Warburg effect. Adaptive metabolic alterations in cancer cells can be attributed to mutations in key metabolic enzymes and transcription factors. The features of the Warburg phenotype may serve as promising markers for the early detection and treatment of tumors. Besides, the glycolytic process of tumors is reversible and could represent a therapeutic target. So-called mono-target therapies are often unsafe and ineffective, and have a high prevalence of recurrence. Their success is hindered by the ability of tumor cells to simultaneously develop multiple chemoresistance pathways. Therefore, agents that modify several cellular targets, such as energy restriction to target tumor cells specifically, have therapeutic potential. Resveratrol, a natural active polyphenol found in grapes and red wine and used in many traditional medicines, is known for its potential as an imitator of caloric restriction, and its therapeutic capacity in tumors. It may affect key processes such as inflammation, angiogenesis, proliferation, metastasis, glucose metabolism, and apoptosis in various cancers because resveratrol acts as a multi-targeting agent by modulating multiple signal transduction pathways. This review article focuses on resveratrol’s ability to modify tumor glucose metabolism and its associated therapeutic capacity. Resveratrol reduces glucose uptake and glycolysis by affecting Glut1, PFK1, HIF-1α, ROS, PDH, and the CamKKβ/AMPK pathway. It also inhibits cell growth, invasion, and proliferation by targeting NF-kB, Sirt1, Sirt3, LDH, PI-3K, mTOR, PKM2, R5P, G6PD, TKT, talin, and PGAM. In addition, resveratrol induces apoptosis by targeting integrin, p53, LDH, and FAK. In conclusion, resveratrol has many potentials to intervene in tumor processes if bioavailability can be increased and this natural compound can be used selectively.

Citation: Brockmueller, A.; Sameri, S.; Liskova, A.; Zhai, K.; Varghese, E.; Samuel, S.M.; Büsselberg, D.; Kubatka, P.; Shakibaei, M. Resveratrol’s Anti-Cancer Effects through the Modulation of Tumor Glucose Metabolism. Cancers 2021, 13, 188. https://doi.org/10.3390/cancers13020188

Received: 18 December 2020; Accepted: 4 January 2021; Published: 7 January 2021

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Keywords: anti-tumor action; combinatorial therapy; tumor glucose metabolism; resveratrol; Warburg phenomenon

1. Introduction

Cancer cells depend heavily on their active metabolism for survival and proliferation. Most tumor cells have an adaptive and altered metabolism characterized by increased aerobic glycolysis and lactate production, leading to a significant pH gradient difference between cancerous and healthy tissues [1]. This well-known feature of cancer metabolism is referred to as the Warburg effect [2]. Indeed, in 1924, the German physiologist and Nobel laureate Otto Warburg observed that tumor cells metabolize glucose differently from healthy cells [2,3]. He reported that unlike typical mammalian tissues, most cancer cells solely “ferment” glucose to lactate, even when sufficient oxygen is present to support mitochondrial oxidative phosphorylation. Furthermore, this metabolic process enables tumor cells to produce sufficient energy to survive and proliferate despite limited resources.

Glycolysis is the primary degradation mechanism that enables mammalian cells to produce energy in the form of ATP through the oxidation of carbon bonds. The final product of glycolysis is either lactate or, after complete oxidation of glucose via the mitochondrial electron transport chain, ATP and CO$_2$ [4]. In notable contrast, glucose uptake increases dramatically in tumors and other rapidly proliferating cells, even in the presence of oxygen and active mitochondria, and thus leads to lactate production. Altered carbohydrate, protein, and lipid metabolism are implicated in cancer cell proliferation and growth, apoptotic resistance, therapeutic resistance, epithelial-mesenchymal transition (EMT), metastasis, invasion, and tumor recurrence [5]. As the hyperactive glycolytic process of tumor cells is reversible, it is a potential target for treatment. Therefore, the use of drugs that mimic energy restriction for selective tumor cells that are “dependent on glycolysis” could be an auspicious anti-cancer approach. In recent years, the so-called mono-target therapies were proven unsafe, ineffective, and expensive. Notably, phytopharmaceuticals derived from fruits and vegetables exhibit promising therapeutic potential against many chronic diseases, including cancer. The plant polyphenol resveratrol (3,5,4′-trihydroxy-trans-stilbene) was firstly isolated from the root of the white hellebore (Veratrum grandiflorum O. Loes) by Takaoka in 1939. Resveratrol and its biological analogs (piceatannol and pterostilbene) were found in peanuts (Arachis spp.), various berry species (Vaccinium sp.) and red wine [6]. Resveratrol is produced as a phytoalexin by plants in response to stress induced by fungi, microbes, or ultraviolet (UV) irradiation [7].

Resveratrol was first shown in 1997 to affect tumor initiation, promotion, and progression [8]. A large number of reports have since demonstrated its broad preventive and therapeutic effects against various cancer types, including gastrointestinal, breast, lung, prostate, and liver tumors. Resveratrol’s therapeutic potential is further underscored by its significant chemopreventive effects in combination with other cytostatic drugs [8].

In traditional medicine, resveratrol has long been used as an herbal remedy. In modern medicine, resveratrol is of great interest as a “multitargeting agent” because of its antioxidant, anti-inflammatory, anti-obesity, anti-diabetic, anti-bacterial, anti-carcinogenic, cardio-protective, and immunomodulating properties [7–10] (Figure 1). Epidemiologically, there is an inverse association between the consumption of red wine and the incidence of cardiovascular diseases in the French population despite its high intake of saturated fats; this phenomenon is called the “French Paradox” [7,11–13]. Resveratrol exerts a broad spectrum of molecular effects associated with the control of cancer development. These include the reduction of glucose uptake and lactate synthesis, and consequent caloric restriction that inhibits proliferation and metastasis, and induces apoptosis [14–18]. Moreover, resveratrol can directly influence and modulate various metabolic enzymes and signal transduction pathways involved in oxidative glycolysis. Indeed, there is a clinical relationship between glucose resorption, diagnosis, and cancer prognosis [19,20].
This review focuses on the intracellular targets of resveratrol, and their roles in the regulation of cellular glucose metabolism and tumor growth, in the interest of improving cancer prevention and treatment.

2. Goal of the Review

This review deals with resveratrol’s tumor control potential, particularly its ability to suppress cancer cell glucose metabolism. We discuss the mechanisms of glucose uptake, metabolism, and degradation, as well as the molecular pathways that directly regulate tumor cell metabolism. Our review summarizes experimental studies on the anti-tumor effects of resveratrol through the modulation of glycolytic processes. Given the well-documented preclinical efficacy of resveratrol against tumor metabolism, we stress the need for targeted clinical research on the effects of resveratrol on cellular metabolic repair.

3. Source of the Data

Data were collected from the biomedical literature by using “resveratrol” and “cancer” or “glucose metabolism” or “glucose uptake” or “glucose transporter” or “Warburg effect” or “tumor microenvironment” or “polyphenols” or “apoptosis” as keywords or medical terms (MeSH) when searching the PubMed database.

4. Glucose Metabolism (Glycolysis) in Tumors and the Warburg Effect

High glucose absorption is necessary for cancer cell metabolism; this process is well regulated and involves several elements, such as growth factors [21] and interactions with the extracellular matrix [22,23]. To fulfill their glucose demands, tumor cells undergo oncogenic alterations to become independent of the processes that ordinarily regulate glucose absorption [24,25]. Essential glycolytic enzymes, glucose transporters, and transcription factors are often dysregulated during tumorigenesis [26].

In healthy cells, glucose uptake is facilitated by specific cell membrane transporters. Hexokinase phosphorylates intracellular glucose to form glucose-6-phosphate, which is subsequently converted to 3-carbon pyruvate in a process that yields NADH and ATP. In the presence of oxygen (aerobic glycolysis), healthy cells convert the intermediate pyruvate into acetyl-CoA and synthesize ATP and CO₂ efficiently through oxidative phosphorylation (rather than glucose fermentation) [4]. In normal differentiated cells, large amounts of lactate are synthesized from pyruvate only if the oxygen supply is insufficient (anaerobic glycolysis).
In contrast, tumor cells are highly dependent on glucose degradation (known as fermentation) \[3,27\], even under aerobic conditions, to meet their high energy requirements; this is known as the Warburg Effect \[28\] (Figure 2, light green area). Interestingly, tumor cells can activate both the Warburg effect and mitochondrial oxidative phosphorylation simultaneously \[29\]. Most tumor cells synthesize large amounts of lactate independent of oxygen availability, which is why their metabolism is often referred to as “aerobic glycolysis”. Otto Warburg initially assumed that tumor cells have defective mitochondria and thus no aerobic respiratory chain \[2\]. This hypothesis was rejected by later research, as mitochondrial function is not impaired in most cancer cells \[30–32\].

Figure 2. Glucose degradation and metabolism in tumor cells. The uptake of glucose by cell membrane glucose transporters (Glut) is followed by its glycolytic degradation to pyruvate. The first step is the phosphorylation of glucose by hexokinase (HK) and, under anaerobic glycolysis and aerobic glycolysis (Warburg effect, light green area), pyruvate is converted to lactate, thereby regenerating NAD+ to supply the glycolytic processes. This pathway represents an energy source for tumor cells and provides intermediates such as ribose-5-phosphate and NADPH, which are essential for cell proliferation. Pyruvate then undergoes oxidative phosphorylation in the mitochondria, which leads to the formation of ATP molecules from the tricarboxylic acid cycle (TCA). Abbreviations: ATP: adenosine triphosphate; ADP: adenosine diphosphate; NAD+: nicotinamide adenine dinucleotide (oxidized form); NADH, nicotinamide adenine dinucleotide (reduced form); NADPH: nicotinamide adenine dinucleotide phosphate (reduced form); TME: tumor microenvironment; TCA: tricarboxylic acid; LDH: lactate dehydrogenase.

After glucose is uptaken by membrane glucose transporters (Glut) that are overexpressed in tumor cells \[33\], it is converted into glucose-6-phosphate by hexokinase II (HK2). It is important to note that HK2 expression is often upregulated in malignant tumor cells \[34–37\], leading to increased glycolysis \[38,39\]. The next enzyme associated with aerobic glycolysis is phosphofructokinase (PFK), which catalyzes the phosphorylation
of fructose-6-phosphate into fructose-1,6-bisphosphate; PFK is upregulated in various breast tumors [40,41]. The next step of aerobic glycolysis is the conversion of fructose-1,6-bisphosphate to glyceraldehyde-3-phosphate, catalyzed by the enzyme aldolase. Notably, aldolase is overexpressed and activated in the lung’s squamous cell carcinoma [42]. Glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) then converts glyceraldehyde-3-phosphate into 1,3-bisphosphoglycerate.

GAPDH overexpression is considered an essential parameter of many tumor types [43–45] and a potential target for the treatment of malignant tumors [46]. In addition, phosphoglycerate mutase 1 (PGAM1) catalyzes the reversible conversion of 3-phosphoglycerate and 2-phosphoglycerate during glycolysis. PGAM1 is overexpressed in various cancer tissues and plays an essential role in cancer progression and metastasis [47]. Moreover, enolase is a key glycolytic enzyme that converts 2-bisphosphate glyceraldehyde into phosphoenolpyruvate. Enolase is overexpressed in pancreatic ductal adenocarcinoma (PDAC) tissue; its expression is correlated with metastasis and poor prognosis in PDAC patients [48]. The enzyme pyruvate kinase M2 (PKM2) catalyzes the irreversible phosphoryl group transfer from phosphoenolpyruvate to pyruvate, from which ATP is formed. In fact, tumor cells often overexpress PKM2 [49–52]. Tumor cells switch to and depend on aerobic glycolysis for survival. Therefore, lactate dehydrogenase (LDH), which catalyzes the conversion of pyruvate to lactate, is the key enzyme for determining the glycolytic phenotype of tumor cells; as such, it could be utilized as a therapeutic target. In fact, LDH inhibition suppresses the progression of lymphomas and pancreatic cancer xenografts [53]. Interestingly, Shim and colleagues (1998) reported that apoptosis could be induced by glucose deficiency in tumor cells [54]; this underscores the functional and survival importance of the Warburg effect. In summary, these findings indicate that the specific suppression of critical glycolytic enzymes could be a fundamental approach to the treatment of malignant tumors.

5. Glycolysis in Tumor Cells and the Pentose Phosphate Pathway (PPP)

Rapidly dividing tumor cells require a large amount of energy to drive their hyperactive proliferation, and a stable and continuous supply of nucleotides for DNA synthesis. These raw materials are supplied by the PPP. Interestingly, numerous PPP enzymes are highly dysregulated in tumors. Glucose-6-phosphate-dehydrogenase (G6PDH), a critical enzyme that determines the growth rate of tumor cells, catalyzes the first step in the PPP, thus producing. Many malignant tumors exhibit elevated G6PDH expression and PPP activity [55–58]. G6PDH knockdown significantly reduced cell proliferation; therefore, the specific inhibition of G6PDH may be an effective avenue for the treatment of glycolytic tumors [59]. The next enzyme in the PPP signaling pathway, 6-phosphogluconate-dehydrogenase (6PGDH), converts 6-phosphogluconate to ribulose-5-phosphate, and reduces NADP to NADPH. 6GPDH is an essential enzyme for lung carcinogenesis, and its specific suppression could be a new method for the treatment of glycolytic lung tumors [60]. The next enzyme in the PPP that converts ribulose-5-phosphate to ribose-5-phosphate is ribulose-5-phosphate isomerase. This enzyme is linked to tumor development [60]. The tumor cells activate de novo nucleotide synthesis to support their rapid proliferation and require ribose-5-phosphate for this purpose. Overall, the PPP, through its regulation of glycolysis, is essential for the survival and proliferation of tumor cells. More interestingly, it can yield promising diagnostic markers for the early detection and treatment of tumors.

6. The Influence of the Tumor Microenvironment on the Warburg Effect

Metabolic alterations associated with increased glycolytic degradation in tumor cells are influenced by both intracellular changes and extracellular factors in the tumor microenvironment [61]. Interestingly, a low pH (due to the Warburg effect) is the most important and consistent feature of the tumor microenvironment [62]. There is a characteristic change in the pH gradient between tumor and normal tissue [1]. Shamim and co-workers demonstrated that a low pH tumor microenvironment, associated with several factors such as reduced vascularization, nutrient deprivation, and hypoxia in the context of the Warburg
effect, weakens tumor cells and supports successful anti-tumor therapy [63]. Fermentation is an essential metabolic pathway in tumor cells that maintain lower pH values (some as low as 6.0) due to lactic acid production and increased CO$_2$ content [64]. The tumor-specific acidic milieu may be an important prerequisite for the effective development and action of many cancer drugs [65–68]. Notably, low pH in normal mammalian cells can cause inter-nucleosomal DNA fragmentation and apoptosis [69].

Moreover, specific influences from the tumor microenvironment can modulate DNA methylation, histone modifications, and miRNA expression, which in turn influence the metabolic processes of the tumor. All glycolytic proteins and enzymes are post-transcriptionally regulated by miRNAs. There is a relationship between the deregulation of miRNAs (such as miRNA-150, miRNA-522-3p, and miRNA-10a) and Glut1 activity [70–72]. Furthermore, essential enzymes such as HK2 and PKM2 are upregulated during aerobic glycolysis in tumors. It has been reported that the identification of hexokinase 2 (HK2) as a direct target of miR-143, and show that reintroduction of miR-143 in the colon cancer cell line DLD-1 leads to decreased lactate secretion. They hypothesized that loss of miR-143-mediated suppression of HK2 may promote glucose metabolism in cancer cells, contributing to the shift toward aerobic glycolysis observed in many tumors [73]. In contrast, the activation of miRNA-155 is associated with the upregulation of HK2 in lung cancer cells [74]. The expression of PKM2 is downregulated in thyroid cancer cells by miRNA-148a and miRNA-326 [75], and in cervical cancer cells by miRNA-let-7a [76]; this consequently inhibits proliferation.

7. Resveratrol: A Multi-Targeted Agent for the Prevention and Treatment of Chronic Diseases, Including Tumors

Resveratrol demonstrates preventive and therapeutic capacities in many chronic human diseases, including cancer. It is well established that resveratrol modulates numerous components of cell signaling pathways. Furthermore, resveratrol’s metabolic [77–81], hepatoprotective [82], neuroprotective [83], cardioprotective [84–86], anti-aging [82], antioxidant [87,88], anti-inflammatory [82,89], anti-diabetic [82], anti-tumor [90], cancer chemopreventive, and anti-mutagenic activities [8] have been demonstrated in recent years (Figure 1). These beneficial properties underscore its applicability in the treatment of various diseases.

Preventing and treating tumors is an ongoing medical challenge. Mono-target therapies are insufficient because they cannot meet the challenges posed by the complex pro-inflammatory tumor microenvironment, which includes numerous interactions, crosstalk’s, and regulatory mechanisms. Therefore, the identification of novel multi-targeting agents is necessary to affect both tumor cells and the multicellular tumor microenvironment. The multi-targeting activities of natural polyphenols were extensively investigated over the past twenty years. In this review, we focus on the well-studied polyphenol resveratrol. Resveratrol’s strength lies in its ability to influence several vital stages of cancer, namely tumor initiation and progression; it also exerts chemopreventive effects [8]. Specifically, it acts as a pluri-targeting agent by modulating signal transduction pathways that affect cell cycle progression, inflammation, proliferation, apoptosis, metastasis, and angiogenesis (Figure 1) in a wide range of cancer types (Table 1).
| Type of Tumor       | Tumor Cells                          | Mode of Action                                                                 | Reference |
|---------------------|--------------------------------------|-------------------------------------------------------------------------------|-----------|
| Breast cancer       | MCF-7 breast cancer cells.            | Suppresses PFK activity, disrupting glucose metabolism and reducing viability in cancer cells. | [15]      |
|                     | T47D cells, BALB/c-\(\nu\) mice.     | Suppresses cancer cell \(^{18}\)F-FDG uptake and glycolytic metabolism, reduces intracellular ROS, and downregulates HIF-1\(\alpha\) accumulation. | [17]      |
|                     | MDA-MB-231 breast cancer cells.      | Induces apoptosis and inhibits growth by activating the \(de\ novo\) ceramide synthesis pathway. | [91]      |
|                     | MCF-7 breast cancer cells.            | Antiproliferative and cytotoxic effects by decreasing Glut1-mediated glucose uptake. | [92]      |
|                     | Lewis lung carcinoma cells, BALB/c-\(\nu\) mice. | Suppresses glucose uptake by targeting ROS-mediated HIF-1\(\alpha\) activation. | [17]      |
| Lung cancer         | NSCLC, xenograft mouse model.        | Impairs HK2-mediated glycolysis and inhibits anchorage-dependent and -independent growth of cells. | [93]      |
|                     | Human lung carcinoma A549 cells.      | Increases glucocerebrosidase expression, intracellular ceramide levels, and apoptosis. | [94]      |
|                     | Human bronchial epithelial cell line BEP2D. | Inhibits the induced expression of CYP1A1 and CYP1B1; changes the formation and metabolism of carcinogenic benzo[a]pyrene metabolites. | [95]      |
| Colon cancer (CRC)  | HT-29 cells, BALB/c-\(\nu\) mice.    | Suppresses glucose uptake by targeting ROS-mediated HIF-1\(\alpha\) activation. | [17]      |
|                     | HCT116 and Caco2 cells.              | Downregulates glucose uptake, glycolytic enzymes (PK, LDH), and VEGF; induces apoptosis. | [96]      |
|                     | CT26 cells, CT26 tumor bearing mice. | Suppresses tumor growth and glucose uptake; increases apoptosis. | [97]      |
|                     | Caco2 and HTC116 colon cancer cells. | Induces oxidative capacities through the CamKKB/AMPK pathway; increases PDH activity. | [98]      |
|                     | HT-29 colon cancer cells.            | Suppresses proliferation and induces apoptosis by targeting PPP and the talin-pFAK. | [99]      |
| Prostate cancer     | PC3 prostate cancer cells.            | Inhibits growth via a metabolic shift from glucose fermentation to mitochondrial respiration. | [100]     |
|                     | PC3 prostate cancer cells.            | Suppresses tumor growth by interfering with glucose fermentation and thereby promoting oxidative respiration. | [101]     |
| Ovarian cancer      | SKOV3 and CaOV3 Ovarian cancer cells. | Reduces glucose uptake and lactate production via suppression of the Akt/mTOR pathway. | [18]      |
|                     | Ovarian cancer cells.                | Inhibits glucose uptake and induces apoptosis by impairing the Akt/Glut1 axis. | [102]     |
|                     | A2780 and SKOV3 ovarian cancer cells. | Anti-proliferative, pro-apoptotic effects through the inhibition of glycolysis and targeting of the AMPK/mTOR pathway. | [103]     |
|                     | Preclinical mouse model of ovarian cancer. | Inhibits glucose uptake with antineoplastic effects; suppresses tumor regrowth after therapy with cisplatin. | [104]     |
| Leukemia            | B-CLL and HCL lymphocytic leukemia.   | Decreases the mitochondrial transmembrane potential, inhibits proliferation and growth, and induces apoptosis. | [105,106] |
|                     | CD95-sensitive leukemia cells, B-leukemic cells. | Promotes apoptosis by depolarizing mitochondrial membranes and activating caspase-9. | [107]     |
### Table 1. Cont.

| Type of Tumor        | Tumor Cells                                      | Mode of Action                                                                 | Reference |
|----------------------|--------------------------------------------------|---------------------------------------------------------------------------------|-----------|
| Liver cancer         | HepG2 cells. suppresses glucose uptake via the Sirt1-dependent p-STAT3 signaling pathway.  | [108]                                                                            |
|                      | HCC, HepG2, Bel-7402, and SMMC-7721 cells.        | suppresses proliferation and migration via Sirt1-mediated post-translational modifications of the PI3K/Akt pathway. | [109] |
| Pancreatic cancer    | Panc-1 human pancreatic cancer cells. suppresses ROS-induced hyperglycemia; inhibits the ERK and p38-MAPK signaling pathways. | [110]                                                                            |
|                      | Pancreatic cancer cells. suppresses proliferation and glucose uptake by targeting HIF-1α. | [111]                                                                            |
|                      | Pancreatic cancer cells. suppresses migration by downregulating ROS/miR-21-mediated activation and glycolysis in PSCs. | [112]                                                                            |

7.1. Resveratrol, Inflammation, and Tumors

Inflammation plays an essential and fundamental role in the development of chronic diseases. Resveratrol exerts anti-inflammatory effects through its influence on various inflammatory signaling cascades. Inflammation is a physiological response aimed to re-establish homeostasis after tissue damage caused by exogenous or endogenous factors [113]. During the inflammatory response, metabolism shifts from anabolism to catabolism ranging from the determination of the activity of adenosine monophosphate (AMP) and nicotinamide adenine dinucleotide (NAD+) by AMP-activated protein kinase (AMPK) and sirtuins. Thus, AMPK signaling and sirtuins functionally couple inflammation and metabolism with gene expression and transcription factors [114].

In addition, the evolutionarily conserved pro-inflammatory transcription factor nuclear factor kappa-light-chain-enhancer of activated B-cells (NF-κB) is activated by a variety of stimuli, including inflammatory cytokines and growth factors, and is significantly upregulated in many cancer cells [115,116]. NF-κB activation and NF-κB-promoting gene products are involved in tumor cell survival, proliferation, and invasion [117]. The resveratrol-Sirt1 signaling pathway significantly downregulates cancer cell migration, viability, clonogenicity, and growth by suppressing NF-κB phosphorylation [118–121], underlining the maintenance of homeostasis provides the energy metabolism balance with the inflammatory reaction [122]. Resveratrol activates the target subcellular histone deacetylase Sirt1 in various human tissues, including tumors [123,124].

7.2. Resveratrol and Tumors

Resveratrol exerts preventive and therapeutic effects on tumors through various mechanisms, such as the modulation of signal transduction cascades and tumor metabolism at different stages of tumor development; it can thereby affect cell proliferation, cell division, apoptosis, inflammation, angiogenesis, and metastasis (Figure 1). Resveratrol inhibits proliferation and migration and induces apoptosis by modulating glucose metabolism in various cancer types, including breast, lung, colorectal, prostate, ovarian leukemia, liver, and pancreatic cancers (Table 1). This occurs either via the caspase-3-, 8-, 9-dependent signaling pathways (receptor-mediated/type I and mitochondrial/type II) or the selective reduction of glucose uptake, transport, and metabolism through the modulation of glycolysis and induction of metabolic reprogramming [14–18,93,96–100,102,103,110,125–135]. Furthermore, resveratrol modulates the glucose metabolism of tumor cells switching from aerobic glycolysis (the Warburg effect; producing ATP and NADPH) to mitochondrial oxidative phosphorylation (Table 1).

Resveratrol is a phytochemical agent that can be used as a multi-targeted drug to supplement chemotherapy. To avoid treatment errors, co-treatment with a non-toxic, dietary,
natural cancer drug that can chemosensitize and treat resistant tumors has potential [136]. Moreover, resveratrol can significantly increase the sensitivity of various cancer cells to cytostatic drugs, and improve these drugs’ action by inhibiting and/or modulating different signaling cascades, including the metabolic pathways (Figure 3) [118,137–142].

Figure 3. Resveratrol’s anti-cancer effects through modulation of tumor glucose metabolism.

7.2.1. Breast Cancer

As mentioned above, tumor cells depend primarily on glycolysis to provide the energy and intermediates required for cell growth and proliferation. The enzyme 6-phosphofructo-1-kinase (PFK) is a key glycolytic enzyme; its activity is directly associated with cellular glucose utilization. Resveratrol directly inhibits PFK activity, decreases Glut1-mediated glucose uptake, and inhibits intracellular ROS, which suppresses HIF-1α accumulation and thereby disrupts glucose metabolism and reduces the viability of breast cancer cells [15,17,98,126] (Table 1).

7.2.2. Lung Cancer

Resveratrol downregulates glucose metabolism, mainly by inhibiting HK2; this is mediated by the Akt signaling pathway and leads to glycolytic suppression and ultimately apoptosis in lung cancer cells [93]. Moreover, resveratrol reduces glycolytic flux and Glut1 expression by targeting ROS-mediated HIF-1α activation in Lewis lung carcinoma tumor-bearing mice [17]. Dasari and colleagues showed that resveratrol induces autophagy in A549 lung cancer cells by upregulating glucosylceramidase beta1 (GBA1), the gene associated with Gaucher disease that codes for glucocerebrosidase, which metabolizes glucosylceramide to ceramide and glucose.

Interestingly, the expression and activity of glucocerebrosidase were significantly increased and simultaneously associated with elevated intracellular ceramide levels; both of these correlated with the occurrence of the unique death features [94]. Gu et al. further reported that resveratrol and arsenic trioxide (ATO) are involved in ROS-mediated ER stress, mitochondrial dysfunction, and apoptosis in A549 human lung adenocarcinoma cells, providing new insights into the molecular mechanisms of resveratrol-mediated ATO sensitization. This synergistic effect was combined with the upregulation of ER stress mark-
ers, including 78 kDa glucose-regulated protein (GRP-78), caspase 12, CCAAT/enhancer-binding protein-homologous protein (CHOP), cytochrome c release, and changes in Bax and Bcl-2 expression [143]. Moreover, Mollerup and colleagues demonstrated that resveratrol exerts chemopreventive effects on lung cancer through the modulation of genes involved in the metabolism of polycyclic aromatic hydrocarbons. Specifically, the inhibition of cytochrome P450 1A1 (CYP1A1) and 1B1 (CYP1B1), and upregulation of microsomal epoxide hydrolase (mEH), resulted in the modified formation of carcinogenic benzo[a]pyrene metabolites in human bronchial epithelial cells [95] (Table 1).

7.2.3. Colorectal Cancer (CRC)

In colorectal cancer cells, resveratrol modulates the lipidomic activity profile, increases oxidative activity, reduces glycolysis, and decreases pentose phosphate activity; it thus reverses the Warburg effect by targeting the pyruvate dehydrogenase complex. Moreover, resveratrol improves the oxidative capacity of colorectal cancer cells via the CamKKβ/AMPK signaling pathway [98], suppresses glucose metabolism and tumor growth in vitro and in vivo [97], induces apoptosis by targeting the pentose phosphate and talin-FAK signaling pathways [99], and suppresses glucose uptake by targeting ROS-mediated HIF-1α activation [17]. Furthermore, treatment of HT29 human CRC cells with resveratrol induces several ER stress markers (phosphorylation of initiation factor-2alpha (eIF-2alpha), ER stress-specific XBP1 splicing, and CHOP) and decreases glycolytic enzymes (pyruvate kinase and LDH) in Caco2 and HCT-116 cells. Simultaneously, resveratrol stimulates GRP-78, and decreases glucose uptake, Akt phosphorylation, and p-mTOR and p-p70S6K levels; these suggest the induction of ER stress. Finally, resveratrol-induced ER-stress leads to apoptosis of CRC cells [96,144,145] (Table 1).

7.2.4. Prostate Cancer

Resveratrol’s anti-tumor effects (on cell growth, hydrogen peroxide production, and mitochondrial network properties) explicitly depend on the predominant oxygen (hypoxic conditions) and glucose levels; this precludes an increased dependence on oxidative phosphorylation. Resveratrol increases ROS production and the expression of the apoptotic biomarkers Bax, p53, and HIF-1α, and inhibits the anti-apoptotic protein Bcl2, thereby promoting cell death. Besides, resveratrol induces apoptosis in prostate cancer cells via the HIF-1α/ROS/p53 signaling pathway [146]. Resveratrol specifically suppresses the nuclear β-catenin protein by inhibiting HIF-1α, possibly in a proteasome-independent manner. It thereby downregulates the β-catenin-mediated transcriptional activity of androgen receptor (AR) signaling. Resveratrol thus suppresses tumor growth induces apoptosis in CRPC [147] (Table 1).

In summary, a large body of evidence shows that resveratrol inhibits the Warburg effect, reduces cancer drug resistance, and sensitizes tumor cells to chemotherapy by targeting and modulating glucose transporters and glycolytic enzymes (Table 1).

8. Resveratrol: Its Impact on Intracellular Molecular Signaling Targets Related to Glucose Metabolism in Tumors

Aberrant metabolism and elevated glycolytic rates in cancer cells are linked to various oncogenic processes such as proliferation, evasion of apoptosis, angiogenesis, and reprogramming of the tumor microenvironment [148]. Metabolomic studies reveal that cancers exhibit diverse metabolic phenotypes [148]. Malignant tumor cells utilize aerobic glycolysis to meet their increased glucose requirements in support of their rapid growth and proliferation; to this end, they overexpress glucose transporters (e.g., Glut1) [33,149–152]. Predominantly glycolytic tumors are characterized by the altered expression of glycolytic enzymes and transporters; therefore, these proteins represent potential targets in anticancer treatment [148].

Through multiple molecular targets, resveratrol suppresses growth, proliferation, and migration, and induces apoptosis, in tumor cells [153,154]. Resveratrol treatment significantly reduces glucose resorption, lactate production, and cell survival in several
human ovarian cancer cell lines in a dose- and time-dependent manner [18,131,155,156]. Interestingly, resveratrol interrupts energy production by stimulating autophagy in tumor cells. Besides, resveratrol blocks glucose uptake in various tumor cells by inhibiting the cell membrane transport of Glut1 via the Akt/mTOR-dependent signaling pathway [16] (Table 2). The Akt/mTOR signaling pathway plays an essential role in the targeting of metabolism by resveratrol in tumor therapy [18,102,155]. Resveratrol also targets “classical” tumor-promoting pathways, such as PI3K/Akt, STAT3/5, and MAPK, which support glycolysis through the upregulation of glycolytic enzymes and glucose transporters [14,148,157–160] (Table 3).

### Table 2. Resveratrol suppresses glucose absorption and metabolism in tumors.

| Experimental Model | Study Type | Finding | Reference |
|--------------------|------------|---------|-----------|
| Nuclear magnetic resonance spectroscopy identified glycolysis as the primary glucose catabolic pathway. | In vitro/LY18 human diffuse large B-cell lymphoma cells. | Inhibits PI-3K signaling and glucose metabolism; induces cell cycle arrest. | [14] |
| Effects of resveratrol on PKM2 expression, and effects on cancer metabolism. | In vitro/HeLa, HepG2, and MCF-7 cells. | Downregulates PKM2 by inhibiting mTOR signaling, reduces glucose uptake, lactate production, and R5P. | [16] |
| Glycolytic metabolism, lactate production assay, hexokinase activity assay, intracellular RO assay, and 18F-FDG uptake. | In vitro/in vivo LLC, HT-29, T47D cells, BALB/c-v mice. | Reduces 18F-FDG uptake, glycolytic metabolism, intracellular ROS, and HIF-1α accumulation. | [17] |
| Growth inhibition assay; [3H]-2-deoxyglucose uptake and lactate assays. | In vitro/multiple human ovarian carcinoma cells. | Induces autophagy; inhibits glycolysis. | [18] |
| Glucose metabolism regulation via Glut1 modulation. | In vitro/human ovarian cancer cells. | Promotes apoptosis by impairing glucose uptake, involving Akt-regulated membrane Glut1 trafficking. | [102] |
| Metabolic and anti-tumor effects of resveratrol. | In vitro/in vivo CT26 colon cancer cells; tumor bearing mice. | Resveratrol-nanoparticles (NP) increase apoptosis and reduce 18F-FDG uptake and ROS. | [97] |
| The effects of resveratrol on glucose metabolism. | In vitro/in vivo human ovarian cancer cells; murine xenograft model. | Inhibits glycolysis and glucose uptake by activating AMPK/mTOR; inhibits growth and metastasis. | [103] |
| The effects of resveratrol on glucose uptake and accumulation, and Glut1. | In vitro/HL-60 and U-937 leukemic cell lines. | Resveratrol blocks Glut1-mediated hexose uptake. | [134] |

### Table 3. Multiple intracellular metabolic enzymes as signaling molecule targets of resveratrol in tumors.

| Molecular Signaling Target | Study Type | Finding | Reference |
|----------------------------|------------|---------|-----------|
| PI3K signaling | In vitro/B cell lymphoma. | Suppresses glucose catabolism; induces growth arrest. | [14] |
| PFK1 | In vitro/human breast cancer cells. | Suppresses glucose uptake and tumor viability. | [15] |
Table 3. Cont.

| Molecular Signaling Target | Study Type                  | Finding                                                     | Reference |
|----------------------------|-----------------------------|-------------------------------------------------------------|-----------|
| mTOR, PKM2, R5P            | In vitro/HeLa, HepG2, and MCF-7 cells. | Suppresses glucose uptake and growth.                       | [16]      |
| HIF-1α/ROS signaling       | In vitro/in vivo HT-29 cells; BALB/c-ν mice. | Suppresses glycolytic metabolism.                           | [17]      |
| Glut1                      | In vitro/in vivo HL-60, U-937, and HT-29 cells; BALB/c-ν mice. | Suppresses glucose uptake.                                  | [17,33,134] |
| FAK, NF-κB, Integrin       | In vitro/human CRC cells.  | Suppresses glucose uptake and invasion; induces apoptosis.  | [119]     |
| Sirt1, PDH, Glut1, NF-κB   | In vitro/human CRC cells.  | Suppresses glucose uptake and invasion; induces apoptosis.  | [120]     |
| Glut1, LDH, Sirt1, Sirt3   | In vitro/human melanoma cells. | Suppresses proliferation; induces cell cycle arrest and apoptosis. | [127]     |
| PDH, CamKKB/AMPK           | In vitro/human CRC cells.  | Induces oxidative capacities; inhibits glycolysis.          | [98]      |
| G6PD, TKT, Talin           | In vitro/human CRC cells.  | Suppresses proliferation and invasion.                      | [99]      |
| HIF-1α/ROS/p53 signaling  | In vitro/prostate cancer cells. | Induces apoptosis.                                           | [146]     |
| HK2                        | In vitro/in vivo.           | Inhibits apoptosis.                                          | [161]     |
| PGAM                       | In vitro/human prostate cancer cells. | Inhibits tumor cell growth.                                  | [162]     |

Beyond the glycolytic enzymes and protein signaling molecules, glycolysis can also be regulated by miRNAs in cancers [148]. Onco-miRNAs are highly expressed in most cancers [163,164]; resveratrol administration in the Panc-1 pancreatic cancer cell line suppressed miRNA-21, leading to the inhibition of ROS-induced activation, invasion, and glycolysis [112]. PKM2, overexpressed in several cancers, was inhibited by resveratrol via the overexpression of miRNA-326 [165]. Resveratrol inhibited pancreatic cancer cell invasion and migration by suppressing ROS/miRNA-21-mediated activation and glycolysis [112]. These results provide further evidence for the association between the metabolic action of resveratrol and its anti-tumor properties (Figure 3).

9. Sirtuins as Major Intracellular Targets for Resveratrol in Modulating Tumor Glucose Metabolism

As previously discussed, resveratrol can alter glucose/carbohydrate metabolism in various cancers. Resveratrol modulates several signaling pathways, and thereby regulates gene expression transcription factor activity [166]. Resveratrol targets Glut1, inhibits cancer cell glucose uptake, and alters glucose utilization. Resveratrol reverses the Warburg effect and specifically targets the pyruvate dehydrogenase (PDH) complex, an important mitochondrial gatekeeper enzyme of energy metabolism, leading to increased PDH activity, inhibiting HK and PFK, and downregulating PKM2 activity [98]. Thus, it suppresses cancer cell proliferation, viability, growth, invasion, EMT, metastasis, and angiogenesis, and activates apoptotic cell death, thereby overcoming multi-drug and radioresistance [15–18,33,98,167]. One of the most important metabolic regulatory pathways stimulated by resveratrol is the molecular signaling pathway dependent on sirtuins (histone deacetylases) [168]. Resveratrol upregulates sirtuin 1 (Sirt1); Sirt1-dependent extensions of the lifespan were initially reported in yeast, worms, and flies [169,170]. Therefore, sirtuins may represent major intracellular targets for resveratrol-mediated modulation of glucose/carbohydrate metabolism in tumors. The seven highly conserved mammalian sirtuin (Sirt1-7) proteins (homologous to the yeast Silent Information Regulator 2, Sir2) are primarily a family of NAD+−dependent histone deacetylases. They modulate various cellular functions, including metabolism, longevity, energy homeostasis, mitochondrial function, and biogenesis, in physiological and pathological conditions [171–173]. The SIRTs, although localized in the nucleus (Sirt1,
Sirt6, and Sirt7), cytoplasm (Sirt2), and mitochondria (Sirt3, Sirt4, and Sirt5) can reportedly translocate depending on various conditions related to the cell cycle, tissue type, developmental stage, stress, and metabolic status; this suggests that SIRT localization can regulate several metabolic pathways [174] (Table 4).

**Table 4. SIRTs and role in metabolism.**

| Sirtuin | Metabolic Pathways Affected |
|---------|----------------------------|
| SIRT1   | Gluconeogenesis; Glycolysis; Insulin Synthesis and Secretion; Cholesterol and Fatty Acid Synthesis |
| SIRT2   | Gluconeogenesis; Triglyceride Synthesis |
| SIRT3   | Glutamine Metabolism; Ketone Body Formation; Urea Cycle; β-Oxidation of Fatty Acids |
| SIRT4   | Glutamine, Leucine, and Carbohydrate Metabolism; β-Oxidation of Fatty Acids |
| SIRT5   | Glycolysis; Tri-Carboxylic Acid Cycle; Ketone Body Formation |
| SIRT6   | Gluconeogenesis; Glycolysis; β-Oxidation of Fatty Acids |
| SIRT7   | Lipid Metabolism |

Resveratrol is a specific activator of Sirt1. Resveratrol promotes the deacetylation of many metabolic transcriptional regulators via Sirt1 in vivo [175]; this is associated with diabetes treatment [176,177], apoptosis [178], inflammation, and neuroprotection [179]. Besides, Sirt1 has significant effects on caloric restriction and life extension in cells [180,181]. Interestingly, several intracellular metabolic pathways modulated by Sirt1 are also altered during tumor development. It should be emphasized that Sirt1 can control many different oncogenic proteins and drugs and thus many cellular metabolic problems [182], such as the proliferator-activated receptor-gamma-coactivator-1 (PGC-1). Indeed, PGC-1 is activated after deacetylation by Sirt1 and regulates mitochondrial gene expression [183,184]. Sirt1 also targets other transcription factors, such as NF-κB [120], PTP1B [185] and the FOXO (Forkhead O box) family [186]. FOXO1 regulates insulin secretion, insulin resistance, and insulin signaling pathways; in turn, it can inhibit cellular glucose uptake and metabolism [185]. Furthermore, Sirt1 activation regulates the expression of many genes that control metabolism, such as pyruvate dehydrogenase lipoamide kinase 4 (PDK4) and PDH. Notably, resveratrol regulates metabolism via the Sirt1-FOXO1 signaling pathway [187].

The anti-aging effects of resveratrol could be mediated through its anti-oxidant, anti-cyclooxygenase, and anti-free radical activities, its effect on the cell cycle in vitro and in vivo, and its stimulation of Sirt1 [169,170,188,189]. Resveratrol treatment mimics the protective effect of caloric restriction against cancer by inducting Sirt1 [160,190]. In estrogen receptor-positive breast cancer cells, resveratrol elevated NAD+/NADH, subsequently activated Sirt1, and in turn activated the AMP-activated kinase (AMPK), a key sensor of cellular energy levels [160]. AMPK activation further inhibits the mTOR pathway and protein translation by inhibiting 4E-BP1, thereby inhibiting cancer cell proliferation [160]. Resveratrol treatment in human NSCLC cell lines upregulated Sirt1; this correlated with the loss of NF-κB function and gene expression, and rendered the cells susceptible to TNF-α-induced apoptosis [191]. Resveratrol treatment mediated a dose-dependent increase in micro-RNA (miRNA-27b) correlated with the Sirt1-dependent improvement in mitochondrial function in C2C12 myoblasts and skeletal muscle [192]. Sirt6, a key regulator of glucose homeostasis and modulator of Glut1, aldolase, PDK1, and PFK1, was induced by resveratrol in FaDu hypopharyngeal carcinoma cells [193,194]. Moreover, Sirt1 plays an essential role in epigenetic modifications of the chromatin pattern and DNA repair by deacetylation [173,195]. In addition, Sirt1 controls the cellular stress response. Therefore, the state and activity of Sirt1 in cancer may play an essential role in cellular responses to epigenetic conditions and treatments.

In pathology, the SIRTs are implicated in cardiovascular diseases, diabetes, neurodegenerative diseases, age-related maladies, and cancer [168,196–200]. In cancers, SIRTs exert tumorigenic/tumor-promoting and tumor suppressor effects (Table 5) [174,196,200,201]. Hence, the application of resveratrol as a chemotherapeutic agent or metabolic modulator in cancers remains controversial and therefore, must be carefully studied. Resveratrol-
mediated activation of Sirt1 signaling promoted human chondrosarcoma cell apoptosis and suppressed proliferation and invasion in two different colorectal cancer cells [120,202]. On the other hand, Sirt1/2/3 and 7 are implicated in breast cancer initiation, progression, metastasis, and multidrug resistance [203–205]. The apparently antagonistic effects of resveratrol depend on its dosage, pharmacokinetic properties, and bioavailability, and the cancer cell culture conditions [174,204,206].

Table 5. SIRTs and cancer: Localization, enzymatic activity, targets, and roles in various cancers.

| Sirtuin | Cellular Location | Histone Targets | Enzymatic Activity | Oncogenic in Cancers | Genes/Targets as Promoter | Suppressor in Cancers | Genes/Targets as Suppressor |
|---------|------------------|-----------------|-------------------|---------------------|--------------------------|----------------------|---------------------------|
| SIRT1   | Nucleus          | H1-K26Ac        | Deacetylase       | TC [207–209]        | c-MYC, Oct4, ZEB1, Nanog, Cripto, Tert, Lin28, STAT5, EGF, FOXO1, p53, Ku70, Rb, EMT pathway, Akt, KRas, PI3K, BRCA1, Survivin, DBC1 | BC [237,238], NSCLC [239], HCC [209,237], OC [231,237], GC [240], PC [237], CRC [241,242], PAC [243], GB [237] | BRCA1, KRas, PI3K, Smad4/β-catenin, RCA1, Survivin |
|         |                  | H3-K9Ac         |                   | CRC [210,211], Leukemia [212,213], RB [214], Glioma [215,216], BC [217–220], NSCLC [217,223,224], GC [225,226], HCC [227–230], OC [231,232], PAC [233,234], SSCC [235], Melanoma [236] | | | |
|         |                  | H4-K16Ac        |                   | PC [209,221,222], NSCLC [217,223,224], GC [225,226], HCC [227–230], OC [231,232], PAC [233,234], SSCC [235], Melanoma [236] | | | |
|         |                  | H4-K20Ac        |                   | | | | |
|         |                  | H3-K9Ac         |                   | | | | |
| SIRT2   | Cytoplasm        | H3-K18Ac        | Deacetylase, Demyristoylation | HCC [244,245], NB [246], PAC [247,248], NSCLC [249], RCC [250], GB [251], SSCC [235], Melanoma [252] | Slug, α-tubulin, c-MYC, Akt/GSK3β/β-catenin axis | OC [253], BC [254], NSCLC [255–259], CCA [260], HCC [254], PC [261], CRC [262], PAC [258,263], SSCC [264], SBCC [265] | CDK4, APC, CDC20, p53, c-MYC, PKM2, KRas |
|         |                  | H3-K56Ac        |                   | | | | |
|         |                  | H4-K16Ac        |                   | | | | |
| SIRT3   | Mitochondria     |                  | Deacetylase       | BLC [266], CRC [267,268], NSCLC [269], Leukemia [270], OSCC [270], OC [271], SSCC [235], Melanoma [272], BC [273] | p53, Akt/PTEN, Bax/Bcl2, Akt, RIP, SHMT2, GDH | PC [274,275], HCC [276–279], PDC [280], OSCC [281], OC [271], TC [282], GC [283–285], PAC [286], SBCC [287], BC [287–289] | c-MYC, PI3K/Akt, mTOR, Bax/Bcl2, p53, RIP, FOXO3A, Wnt/β-catenin, Twist, HIF-1α, SOD, IDH2, Notch1 |
|         |                  |                   |                   | | | | |
| SIRT4   | Mitochondria     | ADP-ribosylase   |                  | SSCC [235], BC [290] | | | |
|         |                  |                   |                   | | | | |
|         |                  |                   |                   | NSCLC [291–293], ESCLC [294], CRC [295–297], GC [291,295,298], HCC [299], RCC [300], OC [291,295], NB [301], BC [291,295,302] | GDH, ERK/Drp1 axis, E-cadherin, LKB1/AMPKα/mTOR Axis | | |
Table 5. Cont.

| Sirtuin | Cellular Location | Histone Targets | Enzymatic Activity | Oncogenic in Cancers | Genes/Targets as Promoter | Suppressor in Cancers | Genes/Targets as Suppressor |
|---------|------------------|-----------------|-------------------|----------------------|--------------------------|-----------------------|---------------------------|
| SIRT5   | Mitochondria     |                 |                   |                      | Glut1, SHMT2, PKM2, E2F1, SDHA, Vimentin, GDH | NB [312], HCC [313], BC [311] | SOD                       |
|         |                  |                 |                   |                      |                          |                       |                           |
| SIRT6   | Nucleus H3-K9Ac | H3-K56Ac        |                   |                      | HCC [314], SSCC [315,316], Melanoma [317,318], NSCLC [319], TC [320], BC [321] | Bax, COX2, Akt, AMPK, Akt/PTEN, JAK2/STAT3, ERK1/2 | HCC [322–326], CRC [327,328], ACC [329], GMB [330], NSCLC [331], OC [332], PAC [327,333], Melanoma [334], BC [335] | PKM2, PTEN/Akt, NF-kB, JAK2/STAT3, Bax, HIF-1α, c-MYC, Twist (EMT), Notch3 |
| SIRT7   | Nucleus H3-K18Ac|                 |                   |                      | CDC4, NF-κB, p38-MAPK, Bax/Bcl2 | OSCC [342], BC [343] | SMAD4, NF-κB, p38-MAPK, TGFβ, EMT signaling |

ACC = Adrenocortical Carcinoma, BC = Breast Cancer, BLC = Bladder Cancer, CC = Cervical Cancer, CCA = Cholangiocarcinoma, CRC = Colorectal Cancer, ESCC = Esophageal Squamous Cell Carcinoma, GBM = Glioblastoma, GC = Gastric Cancer, HCC = Hepatocellular Carcinoma, NB = Neuroblastoma, NSCLC = Non-Small Cell Lung Carcinoma, OC = Ovarian Cancer, OSA = Osteosarcoma, OSCC = Oral Squamous Cell Carcinoma, PAC = Pancreatic Cancer, PC = Prostate Cancer, PDC = Pancreatic Ductal Cancer, RB = Retinoblastoma, RCC = Renal Cell Carcinoma, SBCC = Skin Basal Cell Carcinoma, SSCC = Skin Squamous Cell Carcinoma, TC = Thyroid Cancer. Table adapted from [174,196,344].

10. Pharmacokinetics of Resveratrol: Challenges and Future Perspectives

Resveratrol occurs as two isomers in plants: trans- and cis-resveratrol [156]. The trans-isomer predominates in Nature [345]; it is biologically more active and more frequently studied [346] due to its higher stability [347].

Although resveratrol is extensively studied in preclinical research, its mechanisms of action under different conditions and at different doses remain elusive, as many effects demonstrated in vitro cannot be reproduced in vivo [348]. Several factors contribute to this non-reproducibility and restrict resveratrol’s clinical applicability [349]. One such factor is the compound’s pharmacokinetic profile [348]. Moreover, resveratrol has low systemic bioavailability, which may reduce its efficacy [156,350]. The bioavailability of orally administered resveratrol is less than 1% due to its rapid and extensive metabolism in the intestine and liver [345,346].

10.1. Absorption

Resveratrol’s appreciable solubility in alcohols and low solubility in water affects its absorption [347]. 75% of resveratrol is absorbed at the gastrointestinal level after oral administration in humans [345,346]. In the intestine, resveratrol is absorbed through passive diffusion or forms complexes with membrane transporters, such as integrins. Within the systemic circulation, resveratrol can be found in its free form or as its metabolites (glucuronide, sulfate). Free resveratrol can bind to lipoproteins or albumin; this facilitates its membrane transport and entry into cells via lipoprotein and albumin receptors [347]. The hydroxyl groups in resveratrol’s structure also enable it to associate with proteins and other nutrients. Therefore, resveratrol complexes retain their solubility and can be
absorbed in the small intestine [347]. However, plasma resveratrol concentrations are not affected by protein content [351].

10.2. Metabolism

Resveratrol metabolism occurs via two main pathways [352]. First, the UDP-glucuronosyltransferase (UGT) enzyme family mediates the glucuronidation of resveratrol by catalyzing its conjugation to a glucuronic acid residue (either at the 3 or 4′-hydroxyl group); this alters its biological properties and facilitates its elimination from the body [352]. Critical glucuronide conjugates of resveratrol include resveratrol-4′-O-glucuronide and resveratrol 3-O-glucuronide [156,350,353]. However, the human liver microsomes contain high concentrations of UGT enzymes that preferentially form resveratrol-3-O-glucuronide [352].

10.3. Bioavailability and Tissue Distribution

The bioavailability and tissue distribution of resveratrol are limited. Nevertheless, resveratrol is effective in vivo; this can be explained by the reconversion of resveratrol metabolites into resveratrol in target tissues [347]. The deconjugation of enzymes such as β-glucuronidase and sulfatase and specific tissue accumulation may enhance resveratrol’s efficacy at target sites. After the stable sulfate-conjugated form of resveratrol is delivered to the target tissue, the starting compound can be regenerated to produce beneficial effects in vivo [346]. The enterohepatic recirculation of resveratrol metabolites may also explain resveratrol’s efficacy despite its low bioavailability and rapid metabolism [347].

Furthermore, there is little information on the biological activity of resveratrol metabolites [352], and preclinical research suggests that the bioactivity of glucuronated and sulfated resveratrol metabolites is weaker than that of their parent form [354]. The bioactivity of sulfated conjugates appears to decrease with increasing degrees of sulfation [352]. To the contrary, resveratrol’s beneficial effects can also be associated with its metabolites [347], as they have strong pharmacological activities [355,356]. In addition to its rapid metabolism, 75% of all resveratrol consumed is rapidly excreted. The remaining resveratrol is metabolized, and the maximum observed concentration of free resveratrol is between 1.7% and 1.9% of the initial level [357].

Interestingly, after ingestion, higher concentrations of resveratrol and its metabolites were observed in the right side of the colon than the left side [358]. Lee et al. determined that resveratrol degradation is affected by small intestinal digestion, and that in vitro human digestion decreases resveratrol’s free radical scavenging activity [359]. Nevertheless, a daily dose of 0.5 or 1 g of resveratrol produced sufficient concentrations for anti-carcinogenic effects in the human gastrointestinal tract [358].

10.4. Improving the Biological Effectiveness of Resveratrol

The pharmacokinetics of trans-resveratrol can be affected by administration routes, dosages, and treatment regimens [352]; the plasma concentration of resveratrol is associated with the ingested dose [353]. Orally administered resveratrol, in the form of 500 mg tablets, was well absorbed; the plasma concentrations of trans-resveratrol and its metabolites were within the reported ranges of in vitro efficacy [346]. Moreover, after repeated high dose administration in healthy volunteers, a micromolar concentration of resveratrol and much higher concentrations of its glucuronide and sulfate conjugates were observed in the plasma [360]. However, the plasma concentration of trans-resveratrol remained low despite high doses and a short dosing interval; nevertheless, trans-resveratrol’s pharmacokinetics revealed circadian variations, with higher bioavailability after morning administration [361].

As detailed in Table 6, various approaches to improving resveratrol’s biological efficacy, such as self-emulsifying drug delivery systems [362], liquid micellar formulations [363], layer-by-layer nano formulations [364], oat protein-shellac nanoparticles [365], casein nanoparticles [366], and nanocrystals [367], have yielded promising results. Selective organ targeting is also possible with resveratrol-loaded glycyrrhizic acid-conjugated human
serum albumin nanoparticles (targeting the liver) [368] and trans-resveratrol-loaded mixed micelles (targeting the brain) [369].

Table 6. Recent developments in increasing the biological activities of resveratrol.

| Delivery System                                                                 | Study Details                                                                 | Results                                                                                                                                   | Reference |
|---------------------------------------------------------------------------------|-------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| Self-emulsifying drug delivery systems of resveratrol.                          | In vitro, in vivo (rats).                                                      | Increased solubility, reduced metabolism, and improved its pharmacokinetic profile.                                                    | [362]     |
| Micellar solubilization of resveratrol.                                         | Twelve healthy volunteers (oral administration).                             | Increased oral bioavailability.                                                                                                          | [363]     |
| Layer-by-layer nanoparticles, resveratrol nanocores, and free resveratrol suspension. | In vivo (Wistar rats, oral administration, 20 mg/kg).                       | Layer-by-layer nanoparticles and resveratrol nanocores enhanced systemic exposure compared to free resveratrol.                        | [364]     |
| Oat protein-shellac nanoparticle delivery system.                               | In vitro, in vivo (rat model).                                                | Protected resveratrol in gastric fluid and controlled its release into the small intestine. Improved cell uptake and transport compared to free resveratrol. Increased bioavailability. | [365]     |
| Encapsulation of resveratrol in casein nanoparticles.                           | In vitro, in vivo (rats).                                                      | Oral administration in rats: remained in the gut and reached intestinal epithelium. Produced high plasma levels of resveratrol (sustained for at least 8 h) and similar results for its metabolites. Oral bioavailability was 10 times higher compared to an oral solution of resveratrol. | [366]     |
| Trans-resveratrol nanocrystals.                                                 | In vitro, in vivo (rats).                                                      | Improved oral bioavailability.                                                                                                          | [367]     |
| Resveratrol-loaded glycyrrhizic acid-conjugated human serum albumin nanoparticles. | In vivo (rats; single-dose tail vein injection).                             | Improved bioavailability of resveratrol. Elevated concentrations in the main organs of rats compared to pure resveratrol. Highest concentrations were observed in the liver (promising liver-targeted delivery system). | [368]     |
| Trans-resveratrol-loaded mixed micelles.                                        | In vivo (rats; intravenous administration).                                   | Enhanced pharmacokinetic parameters. Brain targeting.                                                                                   | [369]     |
| Resveratrol-bovine serum albumin nanoparticles (RES-BSANP).                    | In vivo (nude mice; intraperitoneal injection).                               | Improved dispersal and water solubility. Inhibited carcinoma growth in nude mice bearing human primary ovarian tumors.                        | [370]     |

Besides, the combination of resveratrol with other compounds could improve its bioavailability. Piperine, an alkaloid derived from black pepper, can inhibit glucuronidation; it may therefore increase resveratrol’s bioavailability by slowing its metabolism. As shown by Johnson et al., piperine may improve resveratrol’s bioavailability in mice [371]. Furthermore, De Santi et al. showed that quercetin could inhibit sulfotransferase 1A1 (SULT1A1) enzyme activity and thereby decrease the sulfate conjugate of resveratrol. However, this did not significantly increase resveratrol’s bioavailability [372]. Various synthetic resveratrol derivatives, such as hydroxylated, methoxylated, and halogenated derivatives, have also received attention due to their improved pharmacokinetics and biological activity compared to resveratrol [373,374].

11. Clinical Trials with Resveratrol

Promising preclinical findings on resveratrol’s anti-cancer effects have led to investigations into its clinical effects [375]. A study conducted on forty-two healthy volunteers demonstrated resveratrol’s capability to modulate enzymes involved in carcinogen activation and detoxification and thereby prevent carcinogenesis [376]. Resveratrol also exerted chemopreventive effects in women at increased risk of breast cancer by decreasing the methylation of the tumor suppressor RASSF-1a [377]. Similarly, in postmenopausal women with high BMI (BMI ≥ 25 kg/m²), resveratrol exerted favorable effects on hormone-related
breast cancer risk factors (sex steroid hormone-binding globulin and estrogen metabolites) [378]. However, clinical evidence on the metabolic effects of resveratrol remains scarce. An in-depth search of clinical trial records yielded only indirect evidence of resveratrol’s possible effects on tumor metabolism. High concentrations of insulin-like growth factor-1 (IGF-1) and insulin promote carcinogenesis and early tumor growth through anti-apoptotic signaling and PI3K-Akt-mTORC1-mediated metabolic reprogramming. Diabetes and obesity are mainly associated with an increased risk of cancer with the Warburg phenotype [379]. A Warburg-like effect with elevated glycolysis is also present in tumors characterized by chronic treatment with insulin analogs with high affinity for the IGF-1 receptor (IGF1 and X10) [380].

Repeated administration of high-dose resveratrol in forty healthy volunteers reduced circulating IGF-I and IGF-binding protein-3 (IGFBP-3), suggesting that this mechanism is involved in resveratrol’s chemopreventive efficacy [360]. Resveratrol also reduced fasting insulin levels in patients with polycystic ovary syndrome [381]. The Wnt signaling pathway is associated with obesity and diabetes through its effects on cell metabolism, and may also be involved in metabolic reprogramming for cancer [382]. However, resveratrol can modulate the Wnt pathway [383]. Nevertheless, a phase I pilot study on colorectal cancer patients showed that resveratrol-containing freeze-dried grape powder did not inhibit the Wnt signaling pathway in colorectal cancer, but significantly inhibited Wnt expression in normal colon mucosal cells [384]. Importantly, resveratrol is safe and well-tolerated in numerous clinical studies [361,385]. However, resveratrol may be associated with mild to moderate gastrointestinal symptoms (at daily doses of 2.5–5 g) [360] or diarrhea (at twice-daily doses of 2 g) [386].

Targeting cancer cell metabolism with resveratrol could be a promising oncologic approach. However, further clinical research into the effects of resveratrol on tumor metabolism is necessary.

12. Conclusions and Outlook

The increasing incidence of cancer, as well as unfavorable prognoses in the event late-stage diagnosis and/or complications posed by treatment ineffectiveness and chemoresistance necessitate the identification of novel oncologic compounds. While metabolic and cellular signaling changes are relatively well-known processes in cancer development, the targeted manipulation of tumor metabolism can promote rapid progress in cancer treatment [387].

This review article summarizes the metabolic pathways and the associated major enzymes that contribute to the invasion, proliferation, and survival of tumor cells. Interestingly, since tumor cells’ altered metabolic processes are reversible, they represent promising therapeutic targets (Figure 3). Naturally occurring phytochemicals are currently attracting attention in all areas of cancer research [137,388–402]. Among these phytochemicals, resveratrol is one of the best-known polyphenolic compounds. The targeted manipulation of key metabolic enzymes by resveratrol could represent a useful and innovative therapeutic strategy to control tumors. Preclinical research results demonstrate the positive effects of resveratrol on cancer-associated metabolic processes [77–90].

To the contrary, the clinical anti-cancer efficacy of resveratrol through the regulation of tumor metabolism is not sufficiently investigated. Existing clinical trial results only indirectly indicate relationships between resveratrol and cancer metabolism [360,381,384]. Resveratrol’s application in living organisms is hindered by its low bioavailability, rapid metabolism, and pharmacokinetics [156,345,346,386]. Nevertheless, rapid progress is being made in new delivery systems to increase the efficacy of resveratrol [362–369]; this could contribute to the application of resveratrol in cancer treatment in the context of personalized medicine.
**Author Contributions:** A.B., P.K., D.B., M.S. designed the study and took the lead in writing the manuscript with critical input from S.S., A.L., E.V., S.M.S. and K.Z., who contributed to the design and helped with the interpretation of literature data. M.S. provided expert assistance and supervised the preparation of the manuscript. All authors provided feedback and contributed to the final manuscript. All authors have read and agreed to the published version of the manuscript.

**Funding:** S.M.S. and E.V. were supported by the NPRP11S-1214-170101 grant (June 2019-current) awarded to D.B. by the Qatar National Research Fund (QNRF), Doha, Qatar.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Acknowledgments:** We thank Constanze Buhrmann, Sabine Miech, and Andreas Eimannsberger for skilled and excellent technical assistance. We note, that the research was conducted in part for the doctoral thesis of Aranka Brockmueller to be submitted to Fachbereich Humanmedizin, Ludwig-Maximilians-University Munich, Germany.

**Conflicts of Interest:** The authors declare no conflict of interest.

**Abbreviations**

- 6PGDH: 6-phosphogluconate-dehydrogenase
- Ach: Acetylcholine
- AR: Androgen receptor
- ATO: Arsenic trioxide
- Bax: Bcl-2-associated X protein
- Bcl-2: B-cell lymphoma-2
- B-CLL: B-cell chronic lymphocytic leukemia
- CamKKB/AMPK: Ca2+ Calmodulin kinase kinase B/AMP-activated kinase pathway
- CHOP: CCAAT/enhancer-binding protein-homologous protein
- CML: Chronic myelogenous leukemia
- COX-2: Cyclooxygenase-2
- CRC: Colorectal Cancer
- CRPC: Castration-resistant prostate cancer
- CYP1A1: Cytochrome P450, family 1, subfamily A, polypeptide 1
- ECM: Extracellular Matrix
- EMT: Epithelial-to-mesenchymal transition
- FAK: Focal adhesion kinase
- FOXO: Forkhead O box
- G6PD: Glucose-6-phosphate-dehydrogenase
- GBA1: Glucosylceramidase beta 1
- GLUT1: Glucose transporter 1
- GRP 78: Glucose-regulated protein 78
- HBV: Hepatitis B virus
- HCC: Hepatocellular carcinoma
- HCL: Hairy cell leukemia
- HER-2: Human epidermal growth factor receptor-2
- HGF: Hepatocyte growth factor
- HIF-1α: Hypoxia-inducible factor-1 alpha
- HK2: Hexokinase II
- LDH: Lactate dehydrogenase A
- mEH: Microsomal epoxide hydrolase
- MMP: Matrix-metalloprotease
- mTORC1: Mechanistic target of rapamycin complex 1
- NF-kB: Nuclear factor kappa-light-chain-enhancer of activated B-cells
- NQO-1: NAD(P)H quinone oxidoreductase 1
- NSCLC: Non-small-cell lung cancer
- OXPHOS: Oxidative phosphorylation
Cancers 2021, 13, 188

PCCs Prostate cancer cells
PDAC Pancreatic ductal adenocarcinoma
PDH Pyruvate dehydrogenase
PDHk1 Pyruvate dehydrogenase kinase 1
PDHk4 Pyruvate dehydrogenase lipoamide kinase 4
PK 1 6-phosphofructo-1-kinase
PGAM Phosphoglycerate mutase
PGC-1a Proliferator-activated receptor-gamma-coactivator-1
PK M2 Pyruvate kinase M2
PP Phosphate phosphate pathway
pRb Retinoblastoma protein
PSA Prostate-specific antigen
PSCs Pancreatic stellate cells
PTP1b Tyrosine-protein phosphatase non-receptor type 1
R5P Ribose-5-phosphate
ROS Reactive oxygen species
SREBP1 Sterol regulatory element binding protein 1
SULT Human sulfotransferases
TCA Tricarboxylic acid
TCK Transketolase
UGT UDP-glucuronosyltransferase
VDAC1 Voltage-dependent anion channel 1
VEGF Vascular endothelial growth factor
WNT Wnt signaling pathway
XBP1 X-box binding protein 1

References
1. Gerweck, L.E.; Seetharaman, K. Cellular pH gradient in tumor versus normal tissue: Potential exploitation for the treatment of cancer. Cancer Res. 1996, 56, 1194–1198.
2. Warburg, O. On the Origin of Cancer Cells. Science 1956, 123, 309–314. [CrossRef] [PubMed]
3. Warburg, O.; Wind, F.; Negelein, E. The Metabolism of Tumors in the Body. J. Gen. Physiol. 1927, 8, 519–530. [CrossRef] [PubMed]
4. Rolfe, D.F.; Brown, G.C. Cellular energy utilization and molecular origin of standard metabolic rate in mammals. Physiol. Rev. 1997, 77, 731–758. [CrossRef] [PubMed]
5. Vazquez, A.; Kamphorst, J.J.; Markert, E.K.; Schug, Z.T.; Tardito, S.; Gottlieb, E. Cancer metabolism briefly. J. Cell Sci. 2016, 129, 3367–3373. [CrossRef]
6. Nonomura, S.; Kanagawa, H.; Makimoto, A. Chemical Constituents of Polygonaceous Plants. I. Studies on the Components of KO-J O-KON. (Polygonum cuspidatum Sieb. et zucc.). Yakugaku Zasshi J. Pharm. Soc. Jpn. 1963, 83, 988–990. [CrossRef]
7. Fremont, L. Biological effects of resveratrol. Life Sci. 2000, 66, 663–673. [CrossRef]
8. Jang, M.; Cai, L.; Udeani, G.O.; Slowing, K.V.; Thomas, C.F.; Beecher, C.W.W.; Fong, H.H.S.; Farnsworth, N.R.; Kinghorn, A.D.; Mehta, R.G.; et al. Cancer Chemopreventive Activity of Resveratrol, a Natural Product Derived from Grapes. Science 1997, 275, 218–220. [CrossRef]
9. Baur, J.A.; Pearson, K.J.; Price, N.L.; Jamieson, H.A.; Lerin, C.; Kalra, A.; Prabhu, V.V.; Allard, J.S.; Lopez-Lluch, G.; Lewis, K.; et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006, 444, 337–342. [CrossRef]
10. Baur, J.A.; Sinclair, D.A. Therapeutic potential of resveratrol: The in vivo evidence. Nat. Rev. Drug Discov. 2006, 5, 493–506. [CrossRef]
11. Cao, Z.; Li, Y. Potent induction of cellular antioxidants and phase 2 enzymes by resveratrol in cardiomyocytes: Protection against oxidative and electrophilic injury. Eur. J. Pharmacol. 2004, 489, 39–48. [CrossRef] [PubMed]
12. Saldanha, J.F.; Leal, V.D.O.; Stenvinkel, P.; Carraro-Eduardo, J.C.; Mafra, D. Resveratrol: Why Is It a Promising Therapy for Chronic Kidney Disease Patients? Oxid. Med. Cell. Longev. 2013, 2013, 963217. [CrossRef] [PubMed]
13. Catalgol, B.; Batirel, S.; Taga, Y.; Ozer, N.K. Resveratrol: French Paradox Revisited. Front. Pharmacol. 2012, 3, 141. [CrossRef]
14. Faber, A.C.; Dufort, F.J.; Blair, D.; Wagner, D.; Roberts, M.F.; Chiles, T.C. Inhibition of phosphatidylinositol 3-kinase-mediated glucose metabolism coincides with resveratrol-induced cell cycle arrest in human diffuse large B-cell lymphomas. Biochem. Pharmacol. 2006, 72, 1246–1256. [CrossRef] [PubMed]
15. Gomez, L.S.; Zancan, P.; Marcondes, M.C.; Ramos-Santos, L.; Meyer-Fernandes, J.R.; Sola-Penna, M.; Di Silva, D. Resveratrol decreases breast cancer cell viability and glucose metabolism by inhibiting 6-phosphofructo-1-kinase. Biochimie 2013, 95, 1336–1343. [CrossRef]
16. Iqbal, M.A.; Bamezai, R.N. Resveratrol Inhibits Cancer Cell Metabolism by Down Regulating Pyruvate Kinase M2 via Inhibition of Mammalian Target of Rapamycin. *PLoS ONE* **2012**, *7*, e36764. [CrossRef]

17. Jung, K.-H.; Lee, J.H.; Quach, C.H.T.; Paik, J.-Y.; Oh, H.; Park, J.W.; Lee, E.J.; Moon, S.-H.; Lee, K.-H. Resveratrol Suppresses Cancer Cell Glucose Uptake by Targeting Reactive Oxygen Species-Mediated Hypoxia-Inducible Factor-1 Activation. *J. Nucl. Med.* **2013**, *54*, 2161–2167. [CrossRef]

18. Kueck, A.; Opipari, A.W.; Griffith, K.A.; Tan, L.; Choi, M.; Huang, J.; Wahl, H.; Liu, J.R. Resveratrol inhibits glucose metabolism in human ovarian cancer cells. *Gynecol. Oncol.* **2005**, *107*, 450–457. [CrossRef]

19. Almhuaiadeh, A.; Papathanasiou, N.; Bomanji, J. 18F-FDG PET/CT Imaging in Oncology. *Ann. Saudi Med.* **2011**, *31*, 3–13. [CrossRef]

20. Som, P.; Atkins, H.L.; Bandopadhayay, D.; Fowler, J.S.; MacGregor, R.R.; Matsu, K.; Oster, Z.H.; Sacker, D.F.; Shiue, C.Y.; Turner, H.; et al. A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose (F-18): Nontoxic tracer for rapid tumor detection. *J. Nucl. Med.* **1980**, *21*, 670–675. [CrossRef]

21. Thompson, C.B. Rethinking the Regulation of Cellular Metabolism. *Cold Spring Harb. Symp. Quant. Biol.* **2011**, *76*, 23–29. [CrossRef] [PubMed]

22. Grassian, A.R.; Coloff, J.L.; Brugge, J.S. Extracellular Matrix Regulation of Metabolism and Implications for Tumorigenesis. *Cold Spring Harb. Symp. Quant. Biol.* **2011**, *76*, 313–324. [CrossRef] [PubMed]

23. Schafer, Z.T.; Grassian, A.R.; Song, L.; Jiang, Z.; Gerhart-Hines, Z.; Irie, H.Y.; Gao, S.; Puigserver, P.; Brugge, J.S. Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. *Nat. Cell Biol.* **2009**, *461*, 109–113. [CrossRef] [PubMed]

24. Hanahan, D.; Weinberg, R.A. The Hallmarks of Cancer. *Cell* **2000**, *100*, 57–70. [CrossRef]

25. Vogelstein, B.; Kinzler, K.W. Cancer genes and the pathways they control. *Nat. Med.* **2004**, *10*, 789–799. [CrossRef] [PubMed]

26. Sreedhar, A.; Zhao, Y. Dysregulated metabolic enzymes and metabolic reprogramming in cancer cells (Review). *Biomed. Rep.* **2017**, *8*, 3–10. [CrossRef]

27. Eschbach, W. Ber den Stoffwechsel der Ektopie. *Arch. Gynecol. Obstet.* **1956**, *188*, 81–83. [CrossRef]

28. Heiden, M.G.V.; Cantley, L.C.; Thompson, C.B. Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation. *Science* **2009**, *324*, 1029–1033. [CrossRef] [PubMed]

29. Liberti, M.V.; Locasale, J.W. The Warburg Effect: How Does it Benefit Cancer Cells? *Trends Biochem. Sci.* **2016**, *41*, 211–218. [CrossRef] [PubMed]

30. Fantin, V.R.; St-Pierre, J.; Leder, P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. *Cancer Cell* **2006**, *9*, 425–434. [CrossRef] [PubMed]

31. Moreno-Sánchez, R.; Rodríguez-Enriquez, S.; Marín-Hernández, A.; Saavedra, E. Energy metabolism in tumor cells. *FEBS J.* **2007**, *274*, 1393–1418. [CrossRef] [PubMed]

32. Weinhouse, S. The Warburg hypothesis fifty years later. *J. Cancer Res. Clin. Oncol.* **1976**, *87*, 115–126. [CrossRef] [PubMed]

33. Zambrano, A.; Molt, M.; Uribe, E.; Salas, M. Glut 1 in Cancer Cells and the Inhibitory Action of Resveratrol as A Potential Therapeutic Strategy. *Int. J. Mol. Sci.* **2019**, *20*, 3374. [CrossRef] [PubMed]

34. Niederacher, D.; Entian, K.-D. Characterization of Hex2 protein, a negative regulatory element necessary for glucose repression in yeast. *JBC J. Biol. Inorg. Chem.* **1991**, *266*, 201–209. [CrossRef] [PubMed]

35. Herrero, P.; Galindez-Campa, C.; Moreno, F. Transcriptional regulation of the Saccharomyces cerevisiae HXK1, HXK2 and GLK1 genes. *JBIC J. Biol. Inorg. Chem.* **1991**, *26*, 137–144. [CrossRef] [PubMed]

36. Christlieb, S.B.; Strandholdt, C.N.; Olsen, B.B.; Mylam, K.J.; Larsen, T.S.; Nielsen, A.L.; Rohde, M.; Gerke, O.; Olsen, K.E.; Moller, M.B.; et al. Dual time-point FDG PET/CT and FDG uptake and related enzymes in lymphadenopathies: Preliminary results. *Eur. J. Nucl. Med. Mol. Imaging* **2016**, *43*, 1824–1836. [CrossRef]

37. Gu, J.J.; Singh, A.; Xue, K.; Mavis, C.; Barth, M.; Yanamadala, V.; Lenz, P.; Grau, M.; Lenz, G.; Czuczman, M.S.; et al. Up-regulation of hexokinase II contributes to rituximab-chemotherapy resistance and is a clinically relevant target for therapeutic development. *Oncotarget* **2017**, *9*, 4020–4033. [CrossRef]

38. Rempel, A.; Mathupala, S.P.; Griffin, C.A.; Hawkins, A.L.; Pedersen, P.L. Glucose catabolism in cancer cells: Amplification of the gene encoding type II hexokinase. *Cancer Res.* **2006**, *56*, 2468–2471. [CrossRef]

39. Gustamante, E.; Pedersen, P.L. High aerobic glycolysis of rat hepatoma cells in culture: Role of mitochondrial hexokinase. *Proc. Natl. Acad. Sci. USA* **1977**, *74*, 3735–3739. [CrossRef]

40. El-Bacha, T.; de Freitas, M.S.; Sola-Penna, M. Cellular distribution of phosphofructokinase activity and implications to metabolic regulation in human breast cancer. *Mol. Genet. Metab.** 2003**, *79*, 294–299. [CrossRef]

41. Zancan, P.; Sola-Penna, M.; Furtado, C.N.; da Silva, D. Differential expression of phosphofructokinase-1 isoforms correlates with the glycolytic efficiency of breast cancer cells. *Mol. Genet. Metab.** 2010**, *100*, 372–378. [CrossRef] [PubMed]

42. Li, C.; Xiao, Z.; Chen, Z.; Zhang, X.; Li, J.; Wu, X.; Li, X.; Yi, H.; Li, M.; Zhu, G.; et al. Proteome analysis of human lung squamous carcinoma. *Proteomics* **2006**, *6*, 547–558. [CrossRef] [PubMed]

43. Tokunaga, K.; Nakamura, Y.; Sakata, K.; Fujimori, K.; Ohkubo, M.; Sawada, K.; Sakiyama, S. Enhanced expression of a glyceraldehyde-3-phosphate dehydrogenase gene in human lung cancers. *Cancer Res.* **1987**, *47*, 5616–5619. [PubMed]

44. Epner, D.E.; Partin, A.W.; Schalken, J.A.; Isaacs, J.T.; Coffey, D.S. Association of glyceraldehyde-3-phosphate dehydrogenase expression with cell motility and metastatic potential of rat prostatic adenocarcinoma. *Cancer Res.* **1993**, *53*, 1995–1997. [PubMed]
45. Schek, N.; Hall, B.L.; Finn, O.J. Increased glyceraldehyde-3-phosphate dehydrogenase gene expression in human pancreatic adenocarcinoma. Cancer Res. 1988, 48, 6354–6359.

46. Kudryavtseva, A.; Dmitriev, A.A.; Snezhkina, A.V.; Kudryavtseva, A.V. Deregulation of glycolysis in cancer: Glyceraldehyde-3-phosphate dehydrogenase as a therapeutic target. Expert Opin. Ther. Targets 2013, 17, 681–693. [CrossRef]

47. Li, N.; Liu, X. Phosphoglycerate Mutase 1: Its Glycolytic and Non-Glycolytic Roles in Tumor Malignant Behaviors and Potential Therapeutic Significance. OncoTargets Ther. 2020, 13, 1787–1795. [CrossRef]

48. Feng, C.; Gao, Y.; Wang, C.; Yu, X.; Zhang, W.; Guan, H.; Shan, Z.; Teng, W. Aberrant Overexpression of Pyruvate Kinase M2 Is Associated with Aggressive Tumor Features and the BRAF Mutation in Papillary Thyroid Cancer. J. Clin. Endocrinol. Metab. 2013, 98, 1524–1533. [CrossRef]

49. Ahn, Y.S.; Chemeris, G.Y.; Turusov, V.S.; Bannasch, P. Enzymic Pattern of Preneoplastic and Neoplastic Lesions Induced in the Kidney of CBA Mice by 1,2-Dimethylhydrazine. Toxicol. Pathol. 2004, 32, 1476–1484. [CrossRef] [PubMed]

50. Lu, W.; Cao, Y.; Zhang, Y.; Li, S.; Mu, H.; Ju, Y.-P.; Jiang, L.; Dong, P.; et al. Up-regulation of PKM2 promote malignancy and related to adverse prognostic risk factor in human gallbladder cancer. Sci. Rep. 2016, 6, 26351. [CrossRef] [PubMed]

51. Wittwer, J.A.; Robbins, D.; Wang, F.; Codarin, S.; Shen, X.; Kevil, C.G.; Huang, T.-T.; van Remmen, H.; Richardson, A.; Zhao, Y. Enhanced Mitochondrial Respiration Suppresses Tumor Promoter TPA-Induced PKM2 Expression and Cell Transformation in Skin Epidermal JB6 Cells. Cancer Prev. Res. 2011, 4, 1476–1484. [CrossRef]

52. Le, A.; Cooper, C.R.; Gouw, A.M.; Dinavahi, R.; Maitra, A.; Deck, L.M.; Royer, R.E.; Jagt, D.L.V.; Semenza, G.L.; Dang, C.V. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc. Natl. Acad. Sci. USA 2010, 107, 2037–2042. [CrossRef] [PubMed]

53. Shim, H.; Chun, Y.S.; Lewis, B.C.; Dang, C.V. A unique glucose-dependent apoptotic pathway induced by c-Myc. Proc. Natl. Acad. Sci. USA 1998, 95, 1511–1516. [CrossRef] [PubMed]

54. Jonas, S.K.; Benedetto, C.; Flattman, A.; Hammond, R.H.; Micheletti, L.; Riley, C.P.; Riley, P.A.; Spargo, D.J.; Zonca, M.; Slater, T.F. Increased activity of 6-phosphogluconate dehydrogenase and glucose-6-phosphate dehydrogenase in purified cell suspensions and single cells from the uterine cervix in cervical intraepithelial neoplasia. Br. J. Cancer 1992, 66, 185–191. [CrossRef] [PubMed]

55. Epstein, T.; Xu, L.; Gillies, R.J.; Gatenby, R. Separation of metabolic supply and demand: Aerobic glycolysis as a normal physiological response to fluctuating energetic demands in the membrane. Cancer Metab. 2014, 2, 7. [CrossRef] [PubMed]

56. Shamim, U.; Hanif, S.; Albayan, A.; Beck, F.W.J.; Bao, B.; Wang, Z.; Banerjee, S.; Sarkar, F.H.; Mohammad, R.M.; Hadi, S.M.; et al. Resveratrol-induced apoptosis is enhanced in low pH environments associated with cancer. J. Cell. Physiol. 2011, 227, 1493–1500. [CrossRef] [PubMed]

57. Barilla, A.; Melito, D.; Antonov, A.; Vousden, K.H.; Melino, G.; Zolla, L. Metabolic effect of TAp63α: Enhanced glycolysis and pentose phosphate pathway, resulting in increased antioxidant defense. Oncotarget 2014, 5, 7722–7733. [CrossRef]

58. Patra, K.C.; Hay, N. The pentose phosphate pathway and cancer. Trends Biochem. Sci. 2014, 39, 347–354. [CrossRef]

59. Parkins, C.; Stratford, M.; Dennis, M.; Stubbs, M.; Chaplin, D. The relationship between extracellular lactate and tumour pH in a murine tumour model of ischaemia-reperfusion. Br. J. Cancer 1997, 75, 319–323. [CrossRef] [PubMed]

60. Parkinson, C.; Stratford, M.; Dennis, M.; Stubbs, M.; Chaplin, D. The relationship between extracellular lactate and tumour pH in a murine tumour model of ischaemia-reperfusion. Br. J. Cancer 1997, 75, 319–323. [CrossRef] [PubMed]

61. Gandhi, N.; Das, G.M. Metabolic Reprogramming in Breast Cancer and Its Therapeutic Implications. Cells 2019, 8, 89. [CrossRef] [PubMed]

62. Epstein, T.; Xu, L.; Gillies, R.J.; Gatenby, R. Separation of metabolic supply and demand: Aerobic glycolysis as a normal physiological response to fluctuating energetic demands in the membrane. Cancer Metab. 2014, 2, 7. [CrossRef] [PubMed]

63. Shacham, S.; Ambros, V.P.; Han, S.; Harlow, E. The cell transmembrane pH gradient in tumors enhances cytoxicity of specific weak acid chemotherapy agents. Cancer Res. 2001, 61, 4740–4743. [CrossRef]

64. Gerweck, L.E. Tumor pH: Implications for treatment and novel drug design. Semin. Radiat. Oncol. 1998, 8, 176–182. [CrossRef]

65. Barry, M.A.; Eastman, A. Endonuclease activation during apoptosis: The role of cytosolic Ca2+ and pH. Biochem. Biophys. Res. Commun. 1992, 186, 782–789. [CrossRef]

66. Gerweck, L.E. The pH difference between tumor and normal tissue offers a tumor specific target for the treatment of cancer. Drug Resist. Updat. 2000, 3, 49–50. [CrossRef] [PubMed]

67. Gerweck, L.E. The pH difference between tumor and normal tissue offers a tumor specific target for the treatment of cancer. Drug Resist. Updat. 2000, 3, 49–50. [CrossRef] [PubMed]

68. Chen, R.; Lin, J.; Yan, W.; Chen, D. mIR-522-3p Promotes Osteosarcoma Cell Growth by Regulating Glucose Uptake and GLUT1 Expression. OncoTargets Ther. 2019, 12, 9053–9058. [CrossRef] [PubMed]
71. Chen, Y.; Song, Y.; Yu, Y.; Cheng, W.; Tong, X. miRNA-10a promotes cancer cell proliferation in oral squamous cell carcinoma by upregulating GLUT1 and promoting glucose metabolism. Oncol. Lett. 2019, 17, 5441–5446. [CrossRef] [PubMed]

72. Yuan, G.; Zhao, Y.; Wu, D.; Gao, C. Mir-150 Up-Regulates Glut1 and Increases Glycolysis in Osteosarcoma Cells. Asian Pac. J. Cancer Prev. 2017, 18, 1127–1131. [PubMed]

73. Gregersen, L.H.; Skanderup, A.J.; Frankel, L.B.; Wen, J.; Krogh, A.; Lund, A.H. MicroRNA-143 down-regulates Hexokinase 2 in colon cancer cells. BMC Cancer 2012, 12, 232. [CrossRef] [PubMed]

74. Lv, X.; Yao, L.; Zhang, J.; Han, P.; Li, C. Inhibition of microRNA-155 sensitizes lung cancer cells to irradiation via suppression of HK2-modulated glucose metabolism. Mol. Med. Rep. 2016, 14, 1332–1338. [CrossRef] [PubMed]

75. Yu, G.; Sun, W.; Shen, Y.; Hu, Y.; Liu, H.; Li, W.; Wang, Y. PKM2 functions as a potential oncogene and is a crucial target of miR-148A and miR-326 in thyroid tumorigenesis. Am. J. Transl. Res. 2018, 10, 1793–1801.

76. Guo, M.; Zhao, X.; Yuan, J.; Jiang, J.; Li, P. MiR-let-7a inhibits cell proliferation, migration, and invasion by down-regulating PKM2 in cervical cancer. Oncotarget 2017, 8, 28226–28236. [CrossRef]

77. Belgoumdouz, L.; Frémont, L.; Gozzelino, M.-T. Interaction of Transresveratrol with Plasma Lipoproteins. Biochem. Pharmacol. 1998, 55, 811–816. [CrossRef]

78. Fontecave, M.; Lepoivre, M.; Elleingand, E.; Gerez, C.; Guittet, O. Resveratrol, a remarkable inhibitor of ribonucleotide reductase. FEBS Lett. 1995, 389, 277–279. [CrossRef]

79. Gehm, B.D.; McAndrews, J.M.; Chien, P.-Y.; Jameson, J.L. Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc. Natl. Acad. Sci. USA 1997, 94, 14138–14143. [CrossRef]

80. Orsini, F.; Pelizzoni, F.; Verotta, L.; Abruja, T.; Rogers, C.B. Isolation, Synthesis, and Antiplatelet Aggregation Activity of Resveratrol 3-O-β-d-Glucopyranoside and Related Compounds. J. Nat. Prod. 1997, 60, 1082–1087. [CrossRef]

81. Uenobe, F.; Nakamura, S.-I.; Miyazawa, M. Antimutagenic effect of resveratrol against Trp-P-1. Mutat. Res. Mol. Mech. Mutagen. 1997, 373, 197–200. [CrossRef]

82. Kolling, J.; Kolling, J.; de Franceschi, I.D.; Nishihira, V.; Baldissera, M.D.; Pinto, C.G.; Mezzomo, N.J.; Carmo, G.M.D.; Fernandes, L.S.; et al. Resveratrol and resveratrol-hydroxypropyl-β-cyclodextrin complex recovered the changes of creatine kinase and Na+, K+-ATPase activities found in the spleen from streptozotocin-induced diabetic rats. Anais Acad. Bras. Ciênc. 2019, 91, e20181330. [CrossRef] [PubMed]

83. Ahmadi, Y.; Mahmoudi, N.; Yousefi, B.; Karimian, A. The effects of statins with a high hepatoselectivity rank on the extra-hepatic tissues; New functions for statins. Pharmacolet. 2020, 152, 106421. [CrossRef] [PubMed]

84. Hoseini, A.; Namazi, G.; Farrokhian, A.; Reiner, Ž.; Aghadavod, E.; Bahmani, F.; Asemi, Z. The effects of resveratrol on metabolic diseases from India. J. Ethnopharmacol. 2019, 235, 282–292. [CrossRef] [PubMed]

85. Yuan, G.; Zhao, Y.; Wu, D.; Gao, C. Mir-150 Up-Regulates Glut1 and Increases Glycolysis in Osteosarcoma Cells. Asian Pac. J. Cancer Prev. 2017, 18, 1127–1131. [PubMed]

86. Fouad, M.A.; Agha, A.M.; Al Merzabani, M.M.; Shouman, S.A. Resveratrol inhibits proliferation, angiogenesis and induces apoptosis in colon cancer cells. Hum. Exp. Toxicol. 2013, 32, 1067–1080. [CrossRef] [PubMed]

87. Jung, K.-H.; Lee, J.H.; Park, J.W.; Quach, C.H.T.; Moon, S.H.; Cho, Y.-S.; Lee, K.-H. Resveratrol-loaded polymeric nanoparticles suppress glucose metabolism and tumor growth in vitro and in vivo. Int. J. Pharm. 2015, 478, 251–257. [CrossRef]
98. Saunier, E.; Antonio, S.; Regazzetti, A.; Auzeil, N.; Laprèvote, O.; Shay, J.W.; Coumoul, X.; Barouki, R.; Benelli, C.; Huc-Lemarié, L.; et al. Resveratrol reverses the Warburg effect by targeting the pyruvate dehydrogenase complex in colon cancer cells. Sci. Rep. 2017, 7, 1–16. [CrossRef]

99. Vanamala, J.; Radhakrishnan, S.; Reddivari, L.; Bhat, V.B.; Pititsyn, A. Resveratrol suppresses human colon cancer cell proliferation and induces apoptosis via targeting the pentose phosphate and the talin-FAK signaling pathways-A proteomic approach. Proteome Sci. 2011, 9, 49. [CrossRef]

100. Fonseca, J.; Moradi, F.; Maddalena, L.A.; Ferreira-Tollstadius, B.; Selim, S.; Stuart, J.A. Resveratrol integrates metabolic and growth effects in PC3 prostate cancer cells-involvement of prolyl hydroxylase and hypoxia inducible factor-1. Oncol. Lett. 2018, 17, 697–705. [CrossRef]

101. Fonseca, J.; Moradi, F.; Valente, A.J.F.; Stuart, J.A. Oxygen and Glucose Levels in Cell Culture Media Determine Resveratrol’s Effects on Growth, Hydrogen Peroxide Production, and Mitochondrial Dynamics. Antioxidants 2018, 7, 157. [CrossRef] [PubMed]

102. Gwak, H.; Haegeman, G.; Tsang, B.K.; Song, Y.S. Cancer-specific interruption of glucose metabolism by resveratrol is mediated through inhibition of Akt/GLUT1 axis in ovarian cancer cells. Mol. Carcinog. 2014, 54, 1529–1540. [CrossRef] [PubMed]

103. Liu, Y.; Tong, L.; Luo, Y.; Li, X.; Chen, G.; Wang, Y. Resveratrol inhibits the proliferation and induces the apoptosis in ovarian cancer cells via inhibiting glycolysis and targeting AMPK/mTOR signaling pathway. J. Cell. Biochem. 2018, 119, 6162–6172. [CrossRef]

104. Yang, S.H.; Kim, J.S.; Oh, T.J.; Kim, M.S.; Lee, S.W.; Woo, S.K.; Cho, H.S.; Choi, Y.H.; Kim, Y.H.; Rha, S.Y.; et al. Genome-scale analysis of resveratrol-induced gene expression profile in human ovarian cancer cells using a cDNA microarray. Int. J. Oncol. 2003, 22, 741–750. [CrossRef]

105. Billard, C.; Izard, J.-C.; Roman, V.; Kern, C.; Mathiot, C.; Mentz, F.; Kolb, J.-P. Comparative Anti- proliferative and Apoptotic Effects of Resveratrol, (-)-viniferin and Vine-shots Derived Polyphenols (Vineatrols) on Chronic B Lymphocytic Leukemia Cells and Normal Human Lymphocytes. Leuk. Lymphoma 2002, 43, 1991–2002. [CrossRef]

106. Roman, V.; Billard, C.; Kern, C.; Ferry-Dumazet, H.; Izard, J.-C.; Mohammad, R.; Mossalayi, D.M.; Kolb, J.-P. Analysis of resveratrol-induced apoptosis in human B-cell chronic leukaemia. Br. J. Haematol. 2002, 117, 842–851. [CrossRef]

107. Dörrie, J.; Gerauer, H.; Wachter, Y.; Zunino, S.J. Resveratrol induces extensive apoptosis by depolarizing mitochondrial membranes and activating caspase-9 in acute lymphoblastic leukemia cells. Cancer Res. 2001, 61, 4731–4739. [PubMed]

108. Li, Y.; Zhu, W.; Li, J.; Liu, M.; Wei, M. Resveratrol suppresses the STAT3 signaling pathway and inhibits proliferation of high glucose-exposed HepG2 cells partly through SIRT1. Oncol. Rep. 2013, 30, 2820–2828. [CrossRef] [PubMed]

109. Chai, R.; Fu, H.; Zheng, Z.; Liu, T.; Ji, S.; Li, G. Resveratrol inhibits proliferation and migration through SIRT1 mediated post-translational modification of PI3K/AKT signaling in hepatocellular carcinoma cells. Mol. Med. Rep. 2017, 16, 8037–8044. [CrossRef] [PubMed]

110. Cao, L.; Chen, X.; Xiao, X.; Ma, Q.; Li, W. Resveratrol inhibits hyperglycemia-driven ROS-induced invasion and migration of pancreatic cancer cells via suppression of the ERK and p38 MAPK signaling pathways. Int. J. Oncol. 2016, 49, 735–743. [CrossRef] [PubMed]

111. Srivani, G.; Behera, S.K.; Dariya, B.; Aliya, S.; Alam, A.; Nagaraju, G.P. Resveratrol binds and inhibits transcription factor HIF-1 alpha in pancreatic cancer. Exp. Cell Res. 2020, 394, 112126. [CrossRef] [PubMed]

112. Yan, B.; Cheng, L.; Jiang, Z.; Chen, K.; Zhou, C.; Sun, L.; Cao, J.; Qian, W.; Li, J.; Shan, T.; et al. Resveratrol Inhibits ROS-Promoted Activation and Glycolysis of Pancreatic Stellate Cells via Suppression of miR-21. Oxidative Med. Cell. Longev. 2018, 2018, 1–15. [CrossRef] [PubMed]

113. Medzhitov, R. Origin and physiological roles of inflammation. Nature 2008, 454, 428–435. [CrossRef] [PubMed]

114. Zhang, Z.; Lowry, S.F.; Guarente, L.; Haimovich, B. Roles of SIRT1 in the Acute and Restorative Phases following Induction of Inflammation. J. Biol. Chem. 2010, 285, 41391–41401. [CrossRef] [PubMed]

115. Xia, L.; Tan, S.; Zhou, Y.; Lin, J.; Wang, H.; Oyang, L.; Tian, Y.; Liu, L.; Su, M.; Wang, H.; et al. Role of the NFκB-signaling pathway in cancer. Oncotargets Ther. 2018, 11, 2063–2073. [CrossRef]

116. Inoue, J.-I.; Gohda, J.; Akiyama, T.; Semba, K. NF-B activation in development and progression of cancer. Cancer Sci. 2007, 98, 268–274. [CrossRef]

117. Aggarwal, B.B.; Balan, R. Nuclear factor-kappa B links carcinogenic and chemopreventive agents. Front. Biosci. 2009, 1, 45–60. [CrossRef]

118. Buhrmann, C.; Yazdi, M.; Popper, B.; Shayan, P.; Goel, A.; Aggarwal, B.B.; Shakibaeei, M. Resveratrol Chemosensitizes TNF-β-Induced Survival of 5-FU-Treated Colorectal Cancer Cells. Nutrients 2018, 10, 888. [CrossRef]

119. Buhrmann, C.; Shayan, P.; Goel, A.; Shakibaeei, M. Resveratrol Regulates Colorectal Cancer Cell Invasion by Modulation of Focal Adhesion Molecules. Nutrients 2017, 9, 1073. [CrossRef]

120. Buhrmann, C.; Shayan, P.; Popper, B.; Goel, A.; Shakibaeei, M. Sirt1 Is Required for Resveratrol-Mediated Chemopreventive Effects in Colorectal Cancer Cells. Nutrients 2016, 8, 145. [CrossRef]

121. Wu, S.-L.; Sun, Z.-J.; Yu, L.; Meng, K.-W.; Qin, X.-L.; Pan, C.-E. Effect of resveratrol and in combination with 5-FU on murine liver cancer. World J. Gastroenterol. 2004, 10, 3048–3052. [CrossRef] [PubMed]

122. Kauppinen, A.; Suuronen, T.; Ojala, J.; Kaarniranta, K.; Salminen, A. Antagonistic crosstalk between NF-κB and SIRT1 in the regulation of inflammation and metabolic disorders. Cell. Signal. 2013, 25, 1939–1948. [CrossRef] [PubMed]
123. Frazzi, R.; Valli, R.; Tamagnini, I.; Casali, B.; Latruffe, N.; Merli, F. Resveratrol-mediated apoptosis of Hodgkin lymphoma cells involves SIRT1 inhibition and FOXO3a hyperacetylation. *Int. J. Cancer* 2012, 132, 1013–1021. [CrossRef] [PubMed]

124. Ulrich, S.; Loitsch, S.M.; Rau, O.; von Knethen, A.; Brüne, B.; Schubert-Zsilavecz, M.; Stein, J.M. Peroxisome Proliferator–Activated Receptor γ as a Molecular Target of Resveratrol-Induced Modulation of Polyamine Metabolism. *Cancer Res.* 2006, 66, 7348–7354. [CrossRef]

125. Arafa, E.-S.A.; Abdelazeem, A.H.; Arab, H.H.; Omar, H.A. OSU-CG5, a novel energy restriction mimetic agent, targets human cell growth through mitochondrial metabolic reprogramming. *Mol. Carcinog.* 2019, 58, 1876–1885. [CrossRef]

126. Azevedo, C.; Correia-Branco, A.; Araújo, J.; Guimarães, J.T.; Keating, E.; Martel, F. The Chemopreventive Effect of the Dietary Compound Kaempferol on the MCF-7 Human Breast Cancer Cell Line Is Dependent on Inhibition of Glucose Cellular Uptake. *Nutr. Cancer* 2015, 67, 504–513. [CrossRef]

127. George, J.; Nihal, M.; Singh, C.K.; Ahmad, N. 4′-Bromo-resveratrol, a dual Sirtuin-1 and Sirtuin-3 inhibitor, inhibits melanoma cell growth through mitochondrial metabolic reprogramming. *Mol. Carcinog.* 2019, 58, 1876–1885. [CrossRef]

128. Graham, R.M.; Hernández, F.; Puerta, N.; de Angulo, G.; A Webster, K.; Vanni, S. Resveratrol augments ER stress and the cytotoxic effects of glycolytic inhibition in neuroblastoma by downregulating Akt in a mechanism independent of SIRT1. *Exp. Mol. Med.* 2016, 48, e210. [CrossRef] [PubMed]

129. Gwak, H.; Kim, S.; Dhanasakaran, D.N.; Song, Y.S. Resveratrol triggers ER stress-mediated apoptosis by disrupting N-linked glycosylation of proteins in ovarian cancer cells. *Cancer Lett.* 2016, 371, 347–353. [CrossRef]

130. Huang, T.-T.; Lin, H.-C.; Chen, C.-C.; Lu, C.-C.; Wei, C.-F.; Wu, T.-S.; Liu, F.-G.; Lai, H.-C. Resveratrol induces apoptosis of human nasopharyngeal carcinoma cells via activation of multiple apoptotic pathways. *J. Cell. Physiol.* 2010, 226, 720–728. [CrossRef]

131. Le, K.Y.; Wei, C.L.; Min, Z.; Ping, G.J.; Ying, W.; Dan, Z.; Sen, Z. Resveratrol enhances chemosensitivity of renal cell carcinoma. [CrossRef]

132. Arahato, J.; Gonçalves, P.; Martel, F. Modulation of Glucose Uptake in a Human Choriocarcinoma Cell Line (BeWo) by Dietary Bioactive Compounds and Drugs of Abuse. *J. Biomed.* 2008, 144, 177–186. [CrossRef]

133. Azvedo, C.; Correia-Branco, A.; Araújo, J.; Guimarães, J.T.; Keating, E.; Martel, F. The Chemopreventive Effect of the Dietary Compound Kaempferol on the MCF-7 Human Breast Cancer Cell Line Is Dependent on Inhibition of Glucose Cellular Uptake. *Nutr. Cancer* 2015, 67, 504–513. [CrossRef]

134. Mitani, T.; Harada, N.; Tanimori, S.; Nakano, Y.; Inui, H.; Yamaji, R. Resveratrol inhibits hypoxia-inducible factor-1α-mediated androgen receptor signaling and represses tumor progression in castration-resistant prostate cancer. *Cancers* 2015, 6, 2252. [CrossRef]

135. Buhrmann, C.; Shayan, P.; Kraehe, P.; Pedersen, S.B. Resveratrol in metabolic health: An overview of the current evidence and perspectives. *Ann. New York Acad. Sci.* 2013, 1290, 74–82. [CrossRef] [PubMed]

136. Salas, M.; Obando, P.; Ojeda, L.; Ojeda, P.; Pérez, A.; Vargas-Uribé, M.; Rivas, C.I.; Vera, J.C.; Reyes, A.M. Resolution of the direct interaction with and inhibition of the human GLUT1 hexose transporter by resveratrol from its effect on glucose accumulation. *Am. J. Physiol. Physiol. 2013, 305, C90–C99. [CrossRef] [PubMed]

137. Zhou, C.; Qian, W.; Ma, J.; Cheng, L.; Jiang, Z.; Yan, B.; Li, J.; Duan, W.; Sun, L.; Cao, J.; et al. Resveratrol enhances the chemotherapeutic response and reverses the stemness induced by gemcitabine in pancreatic cancer cells via targeting SREBP1. *Cell Transplant.* 2015, 28, 1664–1673. [CrossRef]

138. Cheng, Y.-J.; Chang, M.-Y.; Chang, W.-W.; Wang, W.-K.; Liu, C.-F.; Lin, S.-T.; Lee, C.-H. Resveratrol Enhances Chemosensitivity in colorectal cancer cells in vitro. *Chem. Interact.* 2016, 98, 51–68. [CrossRef]

139. Jie, K.Y.; Wei, C.L.; Min, Z.; Ping, G.J.; Ying, W.; Dan, Z.; Sen, Z. Resveratrol enhances chemosensitivity in colorectal cancer. *Biochem. Pharmacol.* 2015, 98, 51–68. [CrossRef]

140. Li, Y.; Yang, Y.; Liu, X.; Long, Y.; Zheng, Y. PRMT5 Promotes Human Lung Cancer Cell Apoptosis via Akt/Gsk3β Signaling Induced by Resveratrol. *Cell Transplant.* 2019, 28, 1506–1517. [CrossRef]

141. Vinod, B.S.; Nair, H.H.; Vijayakurup, V.; Shabna, A.; Shah, S.; Krishna, A.; Pillai, K.S.; Thakanknachan, S.; Anto, R.J. Resveratrol chemosensitizes HER-2-overexpressing breast cancer cells to docetaxel chemo-resistance by inhibiting docetaxel-mediated activation of HER-2–Akt axis. *Cell Death Discov.* 2015, 1, 15061. [CrossRef] [PubMed]

142. Zhou, C.; Qian, W.; Ma, J.; Cheng, L.; Jiang, Z.; Yan, B.; Li, J.; Duan, W.; Sun, L.; Cao, J.; et al. Resveratrol enhances the chemotherapeutic response and reverses the stemness induced by gemcitabine in pancreatic cancer cells via targeting SREBP1. *Cell Prolif.* 2019, 52, e12514. [CrossRef]

143. Gu, S.; Chen, C.; Jiang, X.; Zhang, Z. ROS-mediated endoplasmic reticulum stress and mitochondrial dysfunction underlie apoptosis induced by resveratrol and arsenic trioxide in A549 cells. *Chem. Interact.* 2016, 245, 100–109. [CrossRef] [PubMed]

144. Park, J.-W.; Woo, K.J.; Lee, J.-T.; Lim, J.H.; Lee, T.; Kim, S.H.; Choi, Y.H.; Kwon, T.K. Resveratrol induces pro-apoptotic endoplasmic reticulum stress in human colon cancer cells. *Oncol. Rep.* 2007, 18, 1269–1273. [CrossRef] [PubMed]

145. Arafa, E.-S.A.; Abdelazeem, A.H.; Arab, H.H.; Omar, H.A. OSU-CG5, a novel energy restriction mimetic agent, targets human colorectal cancer cells in vitro. *Acta Pharmacol. Sin.* 2014, 35, 394–400. [CrossRef]

146. Wang, D.; Gao, Z.; Zhang, X. Resveratrol Induces Apoptosis in Murine Prostate Cancer Cells via Hypoxia-Inducible Factor 1-alpha (HIF-1α)/Reactive Oxygen Species (ROS)/P53 Signaling. *Med. Sci. Monit.* 2018, 24, 8970–8976. [CrossRef]

147. Mitani, T.; Harada, N.; Tanimori, S.; Nakano, Y.; Inui, H.; Yamaji, R. Resveratrol inhibits hypoxia-inducible factor-1α-mediated androgen receptor signaling and represses tumor progression in castration-resistant prostate cancer. *J. Nutr. Sci. Vitaminol.* 2014, 60, 276–282. [CrossRef]

148. Vargheese, E.; Samuel, S.M.; Liskova, A.; Samec, M.; Kubatka, P.; Büsßelberg, D. Targeting Glucose Metabolism to Overcome Resistance to Anticancer Chemotherapy in Breast Cancer. *Cancers* 2020, 12, 2252. [CrossRef]
149. Barron, C.C.; Bilan, P.J.; Tsakiridis, T.; Tsiani, E. Facilitative glucose transporters: Implications for cancer detection, prognosis and treatment. *Metabolism* **2016**, *65*, 124–139. [CrossRef]

150. Labak, C.M.; Wang, P.Y.; Arora, R.; Guda, M.R.; Asuthkar, S.; Tsung, A.J.; Velpula, K.K. Glucose transport: Meeting the metabolic demands of cancer, and applications in glioblastoma treatment. *Am. J. Cancer Res.* **2016**, *6*, 1599–1608.

151. Massari, F.; Ciccarese, C.; Santoni, M.; Iacovelli, R.; Mazzucchelli, R.; Piva, F.; ScarPELLI, M.; Berardi, R.; Tortora, G.; Lopez-Beltran, A.; et al. Metabolic phenotype of bladder cancer. *Cancer Treat. Rev.* **2016**, *45*, 46–57. [CrossRef] [PubMed]

152. Szablewski, L. Expression of glucose transporters in cancers. *Biochim. Biophys. Acta Bioenerg.* **2013**, *1835*, 164–169. [CrossRef] [PubMed]

153. Fang, Y.; Demarco, V.G.; Nicholl, M.B. Resveratrol enhances radiation sensitivity in prostate cancer by inhibiting cell proliferation and promoting cell senescence and apoptosis. *Cancer Sci.* **2012**, *103*, 1090–1098. [CrossRef] [PubMed]

154. Riles, W.L.; Erickson, J.; Nayyar, S.; Atten, M.J.; Attar, B.M.; Holian, O. Resveratrol engages selective apoptotic signals in gastric adenocarcinoma cells. *World J. Gastroenterol.* **2006**, *12*, 5628–5634. [CrossRef]

155. Otipapir, A.W.; Tan, L.; Boitano, A.E.; Sorenson, D.R.; Aurora, A.; Liu, J.R. Resveratrol-induced Autophagy in Ovarian Cancer Cells. *Cancer Res.* **2004**, *64*, 696–703. [CrossRef]

156. Varoni, E.M.; Io Faro, A.F.; Sharifi-Rad, J.; Iriti, M. Anticancer Molecular Mechanisms of Resveratrol. *Front. Nutr.* **2016**, *3*, 8. [CrossRef]

157. Hoehj, G.; Manning, B.D. The PI3K–AKT network at the interface of oncogenic signalling and cancer metabolism. *Nat. Rev. Cancer* **2019**, *20*, 74–88. [CrossRef]

158. Li, M.; Jin, R.; Wang, W.; Zhang, T.; Sang, J.; Li, N.; Han, Q.; Zhao, W.; Li, C.; Liu, Z. STAT3 regulates glycolysis via targeting hexokinase 2 in hepatocellular carcinoma cells. *Onco Targets Ther.* **2017**, *8*, 24777–24784. [CrossRef]

159. Sexton, H.; Hoxhaj, G.; Manning, B.D. The PI3K–AKT network at the interface of oncogenic signalling and cancer metabolism.

160. Fang, Y.; Demarco, V.G.; Nicholl, M.B. Resveratrol enhances radiation sensitivity in prostate cancer by inhibiting cell proliferation and promoting cell senescence and apoptosis. *Cancer Sci.* **2012**, *103*, 1090–1098. [CrossRef] [PubMed]

161. Dai, W.; Wang, F.; Lu, J.; Xia, Y.; He, L.; Chen, K.; Li, J.; Li, S.; Liu, T.; Zheng, Y.; et al. By reducing hexokinase 2, resveratrol induces apoptosis in HCC cells addicted to aerobic glycolysis and inhibits tumor growth in mice. *Onco Targets* **2015**, *6*, 13703–13717. [CrossRef]

162. Narayanan, N.K.; Narayanan, B.A.; Nixon, D.W. Resveratrol-induced cell growth inhibition and apoptosis is associated with modulation of phosphoglycerate mutase B in human prostate cancer cells: Two-dimensional sodium dodecyl sulfate-polyacrylamide gel electrophoresis and mass spectrometry evaluation. *Cancer Detect. Prev.* **2004**, *28*, 443–452. [CrossRef] [PubMed]

163. Sicard, F.; Gayral, M.; Lulka, H.; Buscall, L.; Cordelier, P. Targeting miR-21 for the Therapy of Pancreatic Cancer. *Mol. Ther.* **2013**, *21*, 986–994. [CrossRef] [PubMed]

164. Peralta-Zaragoza, O.; Deas, J.; Meneses-Acosta, A.; de la O-Gómez, F.; Fernández-Tilapa, G.; Gómez-Cerón, C.; Benitez-Boixseanueo, O.; Burguete-Garcia, A.; Torres-Poveda, K.; Bermúdez-Morales, V.H.; et al. Relevance of miR-21 in regulation of tumor suppressor gene PTEN in human cervical cancer cells. *BMC Cancer* **2016**, *16*, 215. [CrossRef] [PubMed]

165. Wu, H.; Wang, Y.; Wu, C.; Yang, P.; Li, H.; Li, Z. Resveratrol Induces Cancer Cell Apoptosis through MiR-326/PKM2-Mediated ER Stress and Mitochondrial Fission. *J. Agric. Food Chem.* **2016**, *64*, 9356–9367. [CrossRef] [PubMed]

166. Thiel, G.; Rössler, O.G. Resveratrol regulates gene transcription via activation of stimulus-responsive transcription factors. *Pharmacol. Res.* **2017**, *117*, 166–176. [CrossRef] [PubMed]

167. Suh, D.H.; Kim, M.K.; Kim, H.S.; Chung, H.H.; Song, Y.S. Cancer-specific Therapeutic Potential of Resveratrol: Metabolic Approach against Hallmarks of Cancer. *Funct. Foods Health Dis.* **2013**, *3*, 332. [CrossRef]

168. Song, J.; Yang, B.; Jia, X.; Li, M.; Tan, W.; Ma, S.; Shi, X.; Feng, L. Distinctive Roles of Sirtuins on Diabetes, Protective or Detrimental? *Front. Endocrinol.* **2019**, *9*, 724. [CrossRef] [PubMed]

169. Howitz, K.T.; Bitterman, K.J.; Cohen, H.Y.; Lamming, D.W.; Lavu, S.; Wood, J.G.; Zipkin, R.E.; Chung, P.; Kisielewski, A.; Zhang, L.-L.; et al. Small molecule activators of sirtuins extend lifespan. *Nature* **2003**, *425*, 191–196. [CrossRef]

170. Wood, J.G.; Rogina, B.; Lavu, S.; Howitz, K.; Helfand, S.L.; Tatar, M.; Sinclair, D. Sirtuin activators mimic caloric restriction and delay ageing in metazoans. *Nat. Cell Biol.* **2004**, *6*, 686–689. [CrossRef]

171. Gaál, Z.; Csernoch, L. Impact of Sirtuin Enzymes on the Altered Metabolic Phenotype of Malignantly Transformed Cells. *Front. Oncol.* **2020**, *10*, 45. [CrossRef]

172. Kaeberlein, M.; McVey, M.; Guarente, L. The SIR2/3/4 complex and SIR2 alone promote longevity in Saccharomyces cerevisiae by two different mechanisms. *Genes Dev.* **1999**, *13*, 2570–2580. [CrossRef] [PubMed]

173. Imai, S.-I.; Armstrong, C.M.; Kaeberlein, M.; Guarente, L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. *Nat. Cell Biol.* **2000**, *4*, 403, 795–800. [CrossRef] [PubMed]

174. Carafa, V.; Altucci, L.; Nebbioso, A. Dual Tumor Suppressor and Tumor Promoter Action of Sirtuins in Determining Malignant Phenotype. *Front. Pharmacol.* **2019**, *10*, 38. [CrossRef]
Cancers 2021, 13, 188

203. Liarte, S.; Alonso-Romero, J.I.; Nicolás, F.J. SIRT1 and Estrogen Signaling Cooperation for Breast Cancer Onset and Progression. Front. Endocrinol. 2018, 9, 552. [CrossRef] [PubMed]

204. Jin, X.; Wei, Y.; Xu, F.; Zhao, M.; Dai, K.; Shen, R.; Yang, S.; Zhang, N. SIRT1 promotes formation of breast cancer through modulating Akt activity. J. Cancer 2018, 9, 2012–2023. [CrossRef] [PubMed]

205. Sinha, S.; Sharma, S.; Vora, J.; Shrivastava, N. Emerging role of sirtuins in breast cancer metastasis and multidrug resistance: Implication for novel therapeutic strategies targeting sirtuins. Pharmacol. Res. 2020, 158, 104880. [CrossRef]

206. Shaito, A.; Posadino, A.M.; Younes, N.; Hasan, H.; Alhababi, D.; Al-Mohannadi, A.; Abdel-Rahman, W.M.; Eid, A.H.; Nasrallah, G.K.; et al. Potential Adverse Effects of Resveratrol: A Literature Review. Int. J. Mol. Sci. 2020, 21, 2084. [CrossRef]

207. Herranz, D.; Maraver, A.; Cañamero, M.; Gómez-López, G.; Ingilada-Pérez, L.; Robledo, M.; Castelblanco, E.; Matías-Guiu, X.; Serrano, M. SIRT1 promotes thyroid carcinogenesis driven by PTEN deficiency. Oncogene 2012, 32, 4052–4056. [CrossRef]

208. Wu, W.; Zhang, L.; Lin, J.; Huang, H.; Shi, B.; Lin, X.; Huang, Z.; Wang, C.; Qiu, J.; Wei, X. Hypermethylation of the H1C promoter and aberrant expression of HIC1/SIRT1 contribute to the development of thyroid papillary carcinoma. Oncotarget 2016, 7, 84416–84427. [CrossRef]

209. Herranz, D.; Muñoz-Martin, M.; Cañamero, M.; Mulero, F.; Martinez-Pastor, B.; Fernandez-Capetillo, O.; Serrano, M. Sirt1 im-

210. Menssen, A.; Hydbring, P.; Kapelle, K.; Vervoorts, J.; Diebold, J.; Lüscher, B.; Larsson, L.-G.; Hermeking, H. The c-MYC oncoprotein, the NAMPT enzyme, the SIRT1-inhibitor DBC1, and the SIRT1 deacetylase form a positive feedback loop. Proc. Natl. Acad. Sci. USA 2011, 109, E187–E196. [CrossRef]

211. Kriegl, L.; Vieth, M.; Kirchner, T.; Menssen, A. Up-regulation of c-MYC and SIRT1 expression correlates with malignant transformation in the serrated route to colorectal cancer. Oncotarget 2012, 3, 1182–1193. [CrossRef]

212. Yuan, H.; Wang, Z.; Li, L.; Zhang, H.; Modi, H.; Horne, D.; Bhatia, R.; Chen, W. Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis. Blood 2012, 119, 1904–1914. [CrossRef]

213. Sasca, D.; Hähnel, P.S.; Szybinski, J.; Khawaja, K.; Kriege, O.; Pante, S.V.; Bullinger, L.; Strand, S.; Strand, D.; Theobald, M.; et al. SIRT1 prevents genotoxic stress-induced p53 activation in acute myeloid leukemia. Blood 2014, 124, 121–133. [CrossRef]

214. Wong, S.; Weber, J.D. Deacetylation of the retinoblastoma tumour suppressor protein by SIRT1. Biochem. J. 2007, 407, 451–460. [CrossRef]

215. Ma, J.-X.; Li, H.; Chen, X.-M.; Yang, X.-H.; Wang, Q.; Wu, M.-L.; Kong, Q.-Y.; Li, Z.-X.; Liu, J. Expression patterns and potential roles of SIRT1 in human medulloblastoma cells in vivo and in vitro. Neuropathology 2013, 33, 7–16. [CrossRef] [PubMed]

216. Li, Y.; Chen, X.; Cui, Y.; Wei, Q.; Chen, S.-Y.; Wang, X. Effects of SIRT1 silencing on viability, invasion and metastasis of human glioma cell lines. Oncol. Lett. 2019, 17, 3701–3708. [CrossRef] [PubMed]

217. Wang, C.; Yang, W.; Dong, F.; Guo, Y.; Tan, J.; Ruan, S.; Huang, T. The prognostic role of SIRT1 expression in solid malignancies: A meta-analysis. Oncotarget 2017, 8, 66343–66351. [CrossRef] [PubMed]

218. Hiraike, H.; Wada-Hiraike, O.; Nakagawa, S.; Saji, S.; Maeda, D.; Miyamoto, Y.; Sone, K.; Tanikawa, M.; Oda, K.; Nakagawa, K.; et al. Expression of DBC1 is associated with nuclear grade and HER2 expression in breast cancer. Exp. Ther. Med. 2011, 2, 1105–1109. [CrossRef] [PubMed]

219. Wu, M.; Wei, W.; Xiao, X.; Guo, J.; Xie, X.; Li, L.; Kong, Y.; Lv, N.; Jia, W.; Zhang, Y.; et al. Expression of SIRT1 is associated with lymph node metastasis and poor prognosis in operable triple-negative and non-triple-negative breast cancer. Med. Oncol. 2012, 29, 3240–3249. [CrossRef]

220. Lee, H.; Kim, K.R.; Noh, S.J.; Park, H.S.; Kwon, K.S.; Park, B.-H.; Jung, S.H.; Youn, H.J.; Ki Lee, B.; Chung, M.J.; et al. Expression of DBC1 and SIRT1 is associated with poor prognosis for breast carcinoma. Hum. Pathol. 2011, 42, 204–213. [CrossRef]

221. Jung-Hynes, B.; Nihal, M.; Zhong, W.; Ahmad, N. Role of Sirtuin Histone Deacetylase SIRT1 in Prostate Cancer. J. Biol. Chem. 2008, 283, 3823–3832. [CrossRef]

222. Huffman, D.M.; Grizzle, W.E.; Bamman, M.M.; Kim, J.-S.; Eltoum, I.A.; Elgavish, A.; Nagy, T.R. SIRT1 Is Significantly Elevated in Mouse and Human Prostate Cancer. Cancer Res. 2007, 67, 6612–6618. [CrossRef]

223. Zhang, Y.; Zhang, M.; Dong, H.; Yong, S.; Li, X.; E Olashaw, N.; A Kruik, P.; Cheng, J.Q.; Bai, W.; Chen, J.; et al. Deacetylation of contactin by SIRT1 promotes cell migration. Oncogene 2008, 28, 445–460. [CrossRef]

224. Tseng, R.-C.; Lee, C.-C.; Hsu, H.-S.; Tzao, C.; Wang, Y.-C. Distinct HIC1-SIRT1-p53 Loop Deregulation in Lung Squamous Carcinoma and Adenocarcinoma Patients. Neoplasia 2009, 11, 763–W11. [CrossRef] [PubMed]

225. Feng, A.N.; Zhang, L.H.; Fan, X.S.; Huang, Q.; Ye, Q.; Wu, H.Y.; Yang, J. Expression of SIRT1 in Gastric Cardiac Cancer and Its Clinicopathologic Significance. Int. J. Surg. Pathol. 2011, 19, 743–750. [CrossRef] [PubMed]

226. Cha, E.J.; Noh, S.J.; Kwon, K.S.; Kim, C.Y.; Park, B.-H.; Park, H.S.; Lee, H.; Chung, M.J.; Kang, M.J.; Lee, D.-G.; et al. Expression of DBC1 and SIRT1 Is Associated with Poor Prognosis of Gastric Carcinoma. Clin. Cancer Res. 2009, 15, 4453–4459. [CrossRef]

227. Chen, J.; Zhang, B.; Wong, N.; Lo, A.W.; To, K.-F.; Chan, A.W.; Ng, M.H.; Ho, C.Y.; Cheng, S.-H.; Lai, P.B.; et al. Sirtuin 1 Is Upregulated in a Subset of Hepatocellular Carcinomas where It Is Essential for Telomere Maintenance and Tumor Cell Growth. Cancer Res. 2011, 71, 4138–4149. [CrossRef] [PubMed]

228. Bae, H.J.; Noh, J.H.; Kim, J.K.; Eun, J.W.; Jung, K.H.; Kim, M.G.; Chang, Y.G.; Shen, Q.; Kim, S.J.; Park, W.S.; et al. MicroRNA-29c functions as a tumor suppressor by direct targeting oncogenic SIRT1 in hepatocellular carcinoma. Oncogene 2013, 33, 2557–2567. [CrossRef]
229. Jang, K.Y.; Noh, S.J.; Lehwald, N.; Tao, G.-Z.; Bellovin, D.I.; Park, H.S.; Moon, W.S.; Felsher, D.W.; Sylvester, K.G. SIRT1 and c-Myc Promote Liver Tumor Cell Survival and Predict Poor Survival of Human Hepatocellular Carcinomas. *PLoS ONE* **2012**, *7*, e45119. [CrossRef]

230. Chen, H.-C.; Jeng, Y.-M.; Yuan, R.-H.; Hsu, H.-C.; Chen, Y.-L. SIRT1 Promotes Tumorigenesis and Resistance to Chemotherapy in Hepatocellular Carcinoma and its Expression Predicts Poor Prognosis. *Ann. Surg. Oncol.* **2011**, *18*, 2011–2019. [CrossRef]

231. Jang, K.Y.; Kim, K.S.; Hwang, S.H.; Kwon, K.S.; Kim, K.R.; Park, H.S.; Park, B.-H.; Chung, M.J.; Kang, M.J.; Lee, D.-G.; et al. Expression and prognostic significance of SIRT1 in ovarian epithelial tumours. *Pathology* **2009**, *41*, 366–371. [CrossRef]

232. Mvunta, D.H.; Miyamoto, T.; Asaka, R.; Yamada, Y.; Ando, H.; Higuchi, S.; Ida, K.; Kashiwa, H.; Shiozawa, T. Overexpression of SIRT1 is Associated with Poor Outcomes in Patients with Ovarian Carcinoma. *Appl. Immunohistochem. Mol. Morphol.* **2017**, *25*, 415–421. [CrossRef] [PubMed]

233. Mvunta, D.H.; Miyamoto, T.; Asaka, R.; Yamada, Y.; Ando, H.; Higuchi, S.; Ida, K.; Kashiwa, H.; Shiozawa, T. Overexpression of SIRT1 is Associated with Poor Outcomes in Patients with Ovarian Carcinoma. *Appl. Immunohistochem. Mol. Morphol.* **2017**, *25*, 415–421. [CrossRef] [PubMed]

234. Zhao, G.; Cui, J.; Zhang, J.-G.; Qin, Q.; Chen, Q.; Yin, T.; Deng, S.-C.; Liu, Y.; Liu, L.; Wang, B.; et al. SIRT1 RNAi knockdown induces apoptosis and senescence, inhibits invasion and enhances chemosensitivity in pancreatic cancer cells. *Gene Ther.* **2011**, *18*, 920–928. [CrossRef] [PubMed]

235. Benavenente, C.A.; Schnell, S.A.; Jacobson, E.L. Effects of Niacin Restriction on Sirtuin and PARP Responses to Photodamage in Human Skin. *PLoS ONE* **2012**, *7*, e42276. [CrossRef] [PubMed]

236. Wilking, M.J.; Singh, C.K.; Nihal, M.; Zhong, W.; Ahmad, N. SIRT1 deacetylase is overexpressed in human melanoma and its small molecule inhibition imparts anti-proliferative response via p53 activation. *Arch. Biochem. Biophys.* **2014**, *563*, 94–100. [CrossRef] [PubMed]

237. Wang, R.-H.; Sengupta, K.; Li, C.; Kim, H.-S.; Cao, L.; Xiao, C.; Kim, S.; Xu, X.; Zheng, Y.; Chilton, B.; et al. Impaired DNA Damage Response, Genome Instability, and Tumorigenesis in SIRT1 Mutant Mice. *Cancer Cell* **2008**, *14*, 312–323. [CrossRef]

238. Wang, R.-H.; Zheng, Y.; Kim, H.-S.; Xu, X.; Cao, L.; Lahusen, T.; Lee, M.-H.; Xiao, C.; Vassilopoulos, A.; Chen, W.; et al. Interplay among BRCA1, SIRT1, and Survivin during BRCA1-Associated Tumorigenesis. *Mol. Cell* **2008**, *32*, 11–20. [CrossRef]

239. Costa-Machado, L.F.; Martí-Hernández, R.; Sanchez-Luengo, M. Angel; Hess, K.; Vales-Villamarín, C.; Barradas, M.; Lynch, C.; de la Nava, D.; Diaz-Ruiz, A.; de Cabo, R.; et al. Sirt1 protects from K-Ras-driven lung carcinogenesis. *EMBO Rep.* **2018**, *19*, e43879. [CrossRef]

240. Yang, Q.; Wang, B.; Gao, W.; Huang, S.; Liu, Z.; Li, W.; Jia, J. SIRT1 Is Downregulated in Gastric Cancer and Leads to G1-phase Arrest via NF-kB/Cyclin D1 Signaling. *Mol. Cancer Res.* **2013**, *11*, 1497–1507. [CrossRef]

241. Firestein, R.; Blander, G.; Michan, S.; Oberdoerffer, P.; Ogino, S.; Campbell, J.; Bhimavarapu, A.; Luikenhuis, S.; de Cabo, R.; Fuchs, C.; et al. The SIRT1 Deacetylase Suppresses Intestinal Tumorigenesis and Colon Cancer Growth. *PLoS ONE* **2008**, *3*, e2020. [CrossRef] [PubMed]

242. Kabra, N.; Li, Z.; Chen, L.; Li, B.; Zhang, X.; Wang, C.; Yeatman, T.; Coppola, D.; Chen, J. Sirt1 Is an Inhibitor of Proliferation and Tumor Formation in Colon Cancer. *J. Biol. Chem.* **2009**, *284*, 18210–18217. [CrossRef] [PubMed]

243. Oon, C.E.; Strell, C.; Yeong, K.Y.; Östman, A.; Prakash, J. SIRT1 inhibition in pancreatic cancer models: Contrasting effects in vitro and in vivo. *Eur. J. Pharmacol.* **2015**, *757*, 59–67. [CrossRef] [PubMed]

244. Chen, J.; Chan, A.W.; To, K.-F.; Chen, W.; Zhang, Z.; Ren, J.; Song, C.; Cheung, Y.-S.; Lai, P.B.; Cheng, S.-H.; et al. SIRT2 overexpression in hepatocellular carcinoma mediates epithelial to mesenchymal transition by protein kinase B/glycogen synthase kinase-3β/β-catenin signaling. *Hepatology* **2013**, *57*, 2287–2298. [CrossRef]

245. Huang, S.; Zhao, Z.; Tang, D.; Zhou, Q.; Li, Y.; Zhou, L.; Yin, Y.; Wang, Y.; Pan, Y.; Dorfman, R.G.; et al. Downregulation of SIRT2 Inhibits Invasion of Hepatocellular Carcinoma by Inhibiting Energy Metabolism. *Transl. Oncol.* **2017**, *10*, 917–927. [CrossRef] [PubMed]

246. Liu, P.Y.; Xu, N.; Malyukova, A.; Scarlett, C.J.; Sun, Y.T.; Zhang, X.D.; Ling, D.; Su, S.-P.; Nelson, C.; Chang, D.K.; et al. The histone deacetylase SIRT2 stabilizes Myc oncoproteins. *Cell Death Differ.* **2012**, *20*, 503–514. [CrossRef]

247. Zhou, W.; Ni, T.K.; Wronska, A.; Glass, B.; Skibinski, A.; Beck, A.; Kuperwasser, C. The SIRT2 Deacetylase Stabilizes Slug to Control Malignancy of Basal-like Breast Cancer. *Cell Rep.* **2016**, *17*, 1302–1317. [CrossRef] [PubMed]

248. Jing, H.; Hu, J.; He, B.; Abril, Y.L.N.; Stupinski, J.; Weiser, K.; Carbonaro, M.; Chiang, Y.-L.; Southard, T.; Giannakakou, P.; et al. SIRT2-Selective Inhibitor Promotes c-Myc Oncoprotein Degradation and Exhibits Broad Anticancer Activity. *Cancer Cell* **2016**, *29*, 607. [CrossRef]

249. Luo, J.; Bao, Y.-C.; Ji, X.-X.; Chen, B.; Deng, Q.-F.; Zhou, S.-W. SPOP promotes SIRT2 deacetylation and suppresses non-small cell lung cancer cell growth. *Biochem. Biophys. Res. Commun.* **2017**, *483*, 880–884. [CrossRef]

250. Wei, R.; He, D.; Zhang, X. Role of SIRT2 in Regulation of Stemness of Cancer Stem-like Cells in Renal Cell Carcinoma. *Cell. Physiol. Biochem.* **2018**, *49*, 2348–2357. [CrossRef]

251. Funato, K.; Hayashi, T.; Echizen, K.; Negishi, L.; Shimizu, N.; Koyama-Nasu, R.; Nasu-Nishimura, Y.; Morishita, Y.; Tabar, V.; Todo, T.; et al. SIRT2-2-mediated inactivation of p73 is required for glioblastoma tumorigenicity. *EMBO Rep.* **2018**, *19*, e45587. [CrossRef]

252. Wilking-Busch, M.J.; Ndiaye, M.A.; Huang, W.; Ahmad, N. Expression profile of SIRT2 in human melanoma and implications for sirtuin-based chemotherapy. *Cell Cycle* **2017**, *16*, 574–577. [CrossRef] [PubMed]
253. Du, Y.; Wu, J.; Zhang, H.; Li, S.; Sun, H. Reduced expression of SIRT2 in serous ovarian carcinoma promotes cell proliferation through disinhibition of CDK4 expression. *Mol. Med. Rep.* 2017, 15, 1638–1646. [CrossRef] [PubMed]

254. Kim, H.-S.; Vassiliopoulos, A.; Wang, R.-H.; Lahusen, T.; Xiao, Z.; Xu, X.; Li, C.; Veenstra, T.D.; Li, B.; Yu, H.; et al. SIRT2 Maintains Genome Integrity and Suppresses Tumorigenesis through Regulating APC/C Activity. *Cancer Cell* 2011, 20, 487–499. [CrossRef] [PubMed]

255. Xu, W.; Jiang, K.; Shen, M.; Qian, Y.; Peng, Y. SIRT2 suppresses non-small cell lung cancer growth by targeting JMJD2A. *Biol. Chem.* 2015, 396, 929–936. [CrossRef] [PubMed]

256. Li, Z.; Huang, J.; Yuan, H.; Chen, Z.; Luo, Q.; Lu, S. SIRT2 inhibits non-small cell lung cancer cell growth through impairing Skp2-mediated p27 degradation. *Oncotarget* 2016, 7, 18927–18939. [CrossRef]

257. Liu, Y.; Cheng, W.; Yin, X.-M.; Jiang, B. The expression of SIRT3 in primary hepatocellular carcinoma and the mechanism of its tumor suppressing effects. *Eur. Rev. Med Pharmacol. Sci.* 2014, 18, 207–209. [CrossRef] [PubMed]

258. Temel, M.; Koç, M.N.; Uluta˘s, S.; Gögêbekan, B. The expression levels of the sirtuins in patients with BCC. *Exp. Dermatol.* 2018, 27, 1638–1646. [CrossRef] [PubMed]

259. Li, S.; Banck, M.; Mujtaba, S.; Zhou, M.-M.; Sugrue, M.M.; Walsh, M.J. p53-Induced Growth Arrest Is Regulated by the Mitochondrial SirT3 Deacetylase. *PLOS ONE* 2010, 5, e10486. [CrossRef]

260. Liu, C.; Huang, Z.; Jiang, H.; Shi, F. The Sirtuin 3 Expression Profile Is Associated with Pathological and Clinical Outcomes in Colon Cancer Patients. *BioMed Res. Int.* 2014, 2014, 1–9. [CrossRef]

261. Wei, Z.; Song, J.; Wang, G.; Cui, X.; Zheng, J.; Tang, Y.; Chen, X.; Li, J.; Cui, L.; Liu, C.-Y.; et al. Deacetylation of serine hydroxymethyl-transferase 2 by SIRT3 promotes colorectal carcinogenesis. *Nat. Commun.* 2018, 9, 1–16. [CrossRef] [PubMed]

262. Xiong, Y.; Li, X.; Zhang, Z.; Jia, L.; Wang, M.; Zhao, J.; Han, Y. SIRT3 is correlated with the malignancy of non-small cell lung cancer. *Int. J. Oncol.* 2017, 50, 903–910. [CrossRef]

263. Marfe, G.; Tafani, M.; Indelicato, M.; Sinibaldi-Salimei, P.; Reali, V.; Pucci, B.; Fini, M.; Russo, M.A. Kaempferol induces apoptosis in two different cell lines via Akt inactivation, Bax and SIRT3 activation, and mitochondrial dysfunction. *J. Cell. Biochem.* 2009, 106, 643–650. [CrossRef]

264. Dong, X.-C.; Jing, L.-M.; Wang, W.-X.; Gao, Y.-X. Down-regulation of SIRT3 promotes ovarian carcinoma metastasis. *Biochem. Biophys. Res. Commun.* 2016, 475, 245–250. [CrossRef]

265. George, J.; Nihal, M.; Singh, C.K.; Zhong, W.; Liu, X.; Ahmad, N. Pro-Proliferative Function of Mitochondrial Sirtuin Deacetylase SIRT3 in Human Melanoma. *J. Investig. Dermatol.* 2016, 136, 809–818. [CrossRef]

266. He, S.; He, C.; Yuan, H.; Xiong, S.; Xiao, Z.; Chen, L. The SIRT 3 Expression Profile is Associated with Pathological and Clinical Outcomes in Human Breast Cancer Patients. *Cell. Physiol. Biochem.* 2014, 34, 2061–2069. [CrossRef]

267. Quan, Y.; Wang, N.; Chen, Q.; Xu, J.; Cheng, W.; Di, M.; Xia, W.; Gao, W.-Q. SIRT3 inhibits prostate cancer by destabilizing oncoprotein c-MYC through regulation of the PI3K/Akt pathway. *Oncotarget* 2015, 6, 26494–26507. [CrossRef]

268. Li, R.; Quan, Y.; Xia, W. SIRT3 inhibits prostate cancer metastasis through regulation of FOXO3A by suppressing Wnt/β-catenin pathway. *Exp. Cell Res.* 2018, 364, 143–151. [CrossRef]

269. Zeng, X.; Wang, N.; Wang, R.; Zhai, H.; Wu, J.; Pu, W. SIRT3 functions as a tumor suppressor in hepatocellular carcinoma. *Tumor Biol.* 2017, 39, 1010428317691178. [CrossRef] [PubMed]

270. Liu, Y.; Cheng, W.; Yin, X.-M.; Jiang, B. The expression of SIRT3 in primary hepatocellular carcinoma and the mechanism of its tumor suppressing effects. *Eur. Rev. Med Pharmacol. Sci.* 2017, 21, 978–998. [PubMed]

271. Bo, Z.; Qin, L.; Zhou, C.-J.; Liu, Y.-L.; Qian, H.; He, S.-B. SIRT3 expression in hepatocellular carcinoma and its impact on proliferation and invasion of hepatoma cells. *Asian Pac. J. Trop. Med.* 2013, 6, 649–652. [CrossRef]
Cancers 2021, 13, 188

279. Zhang, C.Z.; Liu, L.; Cai, M.; Pan, Y.; Fu, J.; Cao, Y.; Yun, J. Low SIRT3 Expression Correlates with Poor Differentiation and Unfavorable Prognosis in Primary Hepatocellular Carcinoma. *PLoS ONE* **2012**, *7*, e51703. [CrossRef]

280. Huang, S.; Guo, H.; Cao, Y.; Xiong, J. MiR-708-5p inhibits the progression of pancreatic ductal adenocarcinoma by targeting Sirt3. *Pathol. Res. Pract.* **2019**, *215*, 794–800. [CrossRef]

281. Miyo, M.; Yamamoto, H.; Konno, M.; Colvin, H.; Nishida, N.; Koseki, J.; Kawamoto, K.; Ogawa, H.; Hamabe, A.; Uemura, M.; et al. Tumour-suppressive function of SIRT4 in human colorectal cancer. *Cancer Manag. Res.* **2018**, *10*, 11849–11856. [CrossRef] [PubMed]

282. Wang, L.; Wang, W.-Y.; Cao, L. SIRT3 inhibits cell proliferation in human gastric cancer through down-regulation of Notch-1. *Int. J. Clin. Exp. Med.* **2015**, *8*, 5263–5271. [PubMed]

283. Zhang, C.Z.; Liu, L.; Cai, M.; Pan, Y.; Fu, J.; Cao, Y.; Yun, J. MiR-708-5p inhibits the progression of pancreatic ductal adenocarcinoma by targeting Sirt3. *Pathol. Res. Pract.* **2019**, *215*, 794–800. [CrossRef]

284. Shackelford, R.; Hirsh, S.; Henry, K.; Abdel-Mageed, A.; Kandil, E.; Coppola, D. Nicotinamide phosphoribosyltransferase and SIRT3 expression are increased in well-differentiated thyroid carcinomas. *Anticancer Res.* **2013**, *33*, 3047–3052. [CrossRef] [PubMed]

285. Yang, B.; Fu, X.; Shao, L.; Ding, Y.; Zeng, D. Aberrant expression of SIRT3 is conversely correlated with the progression and prognosis of human pancreatic cancer. *Pathol. Res. Pract.* **2017**, *213*, 1419–1423. [CrossRef]

286. Huang, S.; Guo, H.; Cao, Y.; Xiong, J. MiR-708-5p inhibits the progression of pancreatic ductal adenocarcinoma by targeting Sirt3. *Pathol. Res. Pract.* **2017**, *213*, 1419–1423. [CrossRef]

287. Finley, L.W.; Carracedo, A.; Lee, J.; Souza, A.; Egia, A.; Zhang, J.; Teruya-Feldstein, J.; Moreira, P.I.; Cardoso, S.M.; Clish, C.B.; et al. SIRT3 Opposes Reprogramming of Cancer Cell Metabolism through HiFH1a Destabilization. *Cancer Cell* **2011**, *19*, 416–428. [CrossRef]

288. Kim, H.-S.; Patel, K.; Muldoon-Jacobs, K.; Bisht, K.S.; Aykin-Burns, N.; Pennington, J.D.; van der Meer, R.; Nguyen, P.; Savage, J.; Owens, K.M.; et al. SIRT3 Is a Mitochondria-Localized Tumor Suppressor Required for Maintenance of Mitochondrial Integrity and Metabolism during Stress. *Cancer Cell* **2010**, *17*, 41–52. [CrossRef]

289. Desouki, M.M.; Doubinskaia, I.; Gius, D.; Abdulkadir, S.A. Decreased mitochondrial SIRT3 expression is a potential molecular biomarker associated with poor outcome in breast cancer. *Hum. Pathol.* **2014**, *45*, 1071–1077. [CrossRef]

290. Huang, G.; Lin, Y.; Zhu, G. SIRT4 is upregulated in breast cancer and promotes the proliferation, migration and invasion of breast cancer cells. *Int. J. Exp. Pathol.* **2017**, *108*, 11849–11856.

291. Jeong, S.M.; Xiao, C.; Finley, L.W.; Lahuens, T.; Souza, A.L.; Pierce, K.; Li, Y.-H.; Wang, X.; Laurent, G.; German, N.J.; et al. SIRT4 Has Tumor-Suppressive Activity and Regulates the Cellular Metabolic Response to DNA Damage by Inhibiting Mitochondrial Glutamine Metabolism. *Cancer Cell* **2013**, *23*, 450–463. [CrossRef]

292. Fu, L.; Dong, Q.; He, J.; Wang, X.; Xing, J.; Wang, E.; Qiu, X.; Li, Q. SIRT4 inhibits malignancy progression of NSCLCs, through mitochondrial dynamics mediated by the ERK-Drp1 pathway. *Oncogene* **2017**, *36*, 2724–2736. [CrossRef]

293. Gong, J.; Wang, H.; Lou, W.; Wang, G.; Tao, H.; Wen, H.; Liu, Y.; Xie, Q. Associations of sirtuins with clinicopathological parameters and prognosis in non–small cell lung cancer. *Cancer Manag. Res.* **2018**, *10*, 3341–3356. [CrossRef]

294. Nakahara, Y.; Yamasaki, M.; Sawada, G.; Miyazaki, Y.; Makino, T.; Kurokawa, Y.; Takiguchi, S.; Mimori, K.; Doki, Y.; Takahashi, T.; et al. Downregulation of SIRT4 Expression Is Associated with Poor Prognosis in Esophageal Squamous Cell Carcinoma. *Oncology* **2016**, *90*, 347–355. [CrossRef] [PubMed]

295. Csibi, A.; Fenndt, S.-M.; Li, C.; Poulogiannis, G.; Choo, A.Y.; Chapski, D.J.; Jeong, S.M.; Dempsey, J.M.; Parkhitko, A.; Morrison, T.; et al. The mTORC1 Pathway Stimulates Glutamine Metabolism and Cell Proliferation by Repressing SIRT4. *Cancer Cell* **2015**, *23*, 1184–1193. [CrossRef] [PubMed]

296. Sun, H.; Huang, D.; Liu, G.; Jian, F.; Zhu, J.; Zhang, L. SIRT4 acts as a tumor suppressor in gastric cancer by inhibiting cancer proliferation, migration and invasion. *Cancer Manag. Res.* **2020**, *12*, 2606–2612. [CrossRef]

297. Wang, Y.-Q.; Wang, H.-L.; Xu, J.; Tan, J.; Fu, L.-N.; Wang, J.-L.; Zou, T.-H.; Sun, D.-F.; Gao, Q.-Y.; Chen, Y.-X.; et al. Sirtuin5 contributes to colorectal carcinogenesis by enhancing glutaminolysis in a deglutarylation-dependent manner. *Nat. Commun.* **2018**, *9*, 1–15. [CrossRef] [PubMed]

298. Wang, L.; Wang, W.-Y.; Cao, L. SIRT3 inhibits cell proliferation in human gastric cancer through down-regulation of Notch-1. *Int. J. Clin. Exp. Med.* **2015**, *8*, 5263–5271. [PubMed]

299. Wang, Y.; Du, L.; Liang, X.; Meng, P.; Bi, L.; Wang, Y.; Wang, C.; Tang, B. Sirtuin 4 Depletion Promotes Hepatocellular Carcinoma Tumorigenesis Through Regulating Adenosine-Monophosphate–Activated Protein Kinase Alpha/Mammalian Target of Rapamycin Axis in Mice. *Hepatol.** 2019**, *70*, 1614–1631. [CrossRef]

300. Wang, C.; Piao, C.; Liu, J.; Zhang, Z.; Zhu, Y.; Kong, C. Mammalian SIRT4 is a tumor suppressor of clear cell renal cell carcinoma by inhibiting cancer proliferation, migration and invasion. *Cancer Biomark.* **2020**, *29*, 453–462. [CrossRef]
304. Du, Z.; Liu, X.; Chen, T.; Gao, W.; Wu, Z.; Hu, Z.; Wei, D.; Gao, C.; Li, Q. Targeting a Sirt5-Positive Subpopulation Overcomes Multidrug Resistance in Wild-Type Kras Colorectal Carcinomas. Cell Rep. 2018, 22, 2677–2689. [CrossRef] [PubMed]

305. Yang, X.; Wang, Z.; Li, X.; Liu, B.; Liu, M.; Liu, L.; Chen, S.; Ren, M.; Wang, Y.; Yu, M.; et al. SHMT2 Desuccinyllation by SIRT5 Drives Cancer Cell Proliferation. Cancer Res. 2018, 78, 372–386. [CrossRef] [PubMed]

306. Lv, X.-B.; Liu, L.; Cheng, C.; Yu, B.; Xiong, L.; Hu, K.; Tang, J.; Zeng, L.; Sang, Y. SUN2 exerts tumor suppressor functions by suppressing the Warburg effect in lung cancer. Sci. Rep. 2015, 5, 17940. [CrossRef] [PubMed]

307. Lu, W.; Zuo, Y.; Feng, Y.; Zhang, M. SIRT5 facilitates cancer cell growth and drug resistance in non-small cell lung cancer. Tumor Biol. 2014, 35, 10699–10705. [CrossRef] [PubMed]

308. Chang, L.; Xi, L.; Liu, Y.; Liu, R.; Wu, Z.; Jian, Z. SIRT5 promotes cell proliferation and invasion in hepatocellular carcinoma by targeting EZF2. Mol. Med. Rep. 2017, 17, 342–349. [CrossRef]

309. Ma, Y.; Qi, Y.; Wang, L.; Zheng, Z.; Zhang, Y.; Zheng, J. SIRT5-mediated SDHA desuccinyllation promotes clear cell renal cell carcinoma tumorigenesis. Free. Radic. Biol. Med. 2019, 134, 458–467. [CrossRef]

310. Park, J.; Chen, K.; Park, J.; Pak, M.; Verhaegen, M.; Fullen, D.; Scott, D.; Osterman, A.; Wang, M.; Andea, A.; et al. Human Melanoma Cell Need SIRT5 to Survive. Free. Radic. Biol. Med. 2016, 100, S128. [CrossRef]

311. Xu, L.; Che, X.; Wu, Y.; Song, N.; Shi, S.; Wang, S.; Li, C.; Zhang, L.; Zhang, X.; Qu, X.; et al. SIRT5 as a biomarker for response-suppressing the Warburg effect in lung cancer. Sci. Rep. 2015, 5, 17940. [CrossRef] [PubMed]

312. Li, F.; He, X.; Ye, D.; Lin, Y.; Yu, H.; Yao, C.; Huang, L.; Zhang, J.; Wang, F.; Xu, S.; et al. NADP+-IDH Mutations Promote Oxidative Stress and Induce PKC Delta Activation through SIRT6 Stabilization to Suppress Tumor Formation. Cell Rep. 2013, 11, 188–196. [CrossRef] [PubMed]

313. Chen, X.; Tian, M.; Sun, R.; Zhang, M.; Zhou, L.; Jin, L.; Chen, L.; Zhou, W.; Duan, K.; Chen, Y.; et al. SIRT5 inhibits peroxisomal ACOX 1 to prevent oxidative damage and is downregulated in liver cancer. EMBO Rep. 2018, 19, e45124. [CrossRef] [PubMed]

314. Ran, L.-K.; Chen, Y.; Zhang, Z.-Z.; Tao, N.-N.; Ren, J.-H.; Zhou, L.; Tang, H.; Chen, X.; Chen, K.; Li, W.-Y.; et al. SIRT6 Overexpression Potentiates Apoptosis Evasion in Hepatocellular Carcinoma via BCL2-Associated X Protein–Dependent Apoptotic Pathway. Clin. Cancer Res. 2016, 22, 3372–3382. [CrossRef] [PubMed]

315. Ning, S.; Ma, S.; Saleh, A.Q.; Guo, L.; Zhao, Z.; Chen, Y. SHMT2 Overexpression Predicts Poor Prognosis in Intrahepatic Cholangiocarcinoma. Gastroenterol. Res. Pract. 2018, 2018, 1–6. [CrossRef] [PubMed]

316. Lefort, K.; Brooks, Y.; Ostan, P.; Cario-André, M.; Calpini, V.; Guinae-Viniegra, J.; Albigier-Hegyi, A.; Hoetzenecker, W.; Kolschoten, I.; Wagner, E.F.; et al. A miR-34a-SIRT6 axis in the squamous cell differentiation network. Mol. Cell. Biochem. 2019, 449, 1–10. [CrossRef]

317. Garcia-Peterson, L.M.; Ndiaye, M.A.; Singh, C.K.; Chhabra, G.; Huang, W.; Ahmad, N. SIRT6 histone deacetylase functions as a potential oncogene in human melanoma. Genes Cancer 2017, 8, 701–712. [CrossRef] [PubMed]

318. Wang, L.; Guo, W.; Ma, J.; Dai, W.; Liu, L.; Guo, S.; Chen, J.; Wang, H.; Yang, Y.; Chunying, L.; et al. Aberrant SIRT6 expression contributes to melanoma growth: Role of the autophagy paradox and IGF-AKT signaling. Autophagy 2017, 14, 518–533. [CrossRef]

319. Azuma, Y.; Yokobori, T.; Mogi, A.; Altan, B.; Yajima, T.; Kosaka, T.; Onozato, R.; Yamaki, E.; Asao, T.; Nishiyama, M.; et al. SIRT6 expression is associated with poor prognosis and chemosensitivity in patients with non-small cell lung cancer. J. Surg. Oncol. 2015, 112, 224–226. [CrossRef]

320. Garcia-Peterson, L.M.; Ndiaye, M.A.; Singh, C.K.; Chhabra, G.; Huang, W.; Ahmad, N. SIRT6 histone deacetylase functions as a potential oncogene in human melanoma. Genes Cancer 2017, 8, 701–712. [CrossRef] [PubMed]

321. Wang, L.; Guo, W.; Ma, J.; Dai, W.; Liu, L.; Guo, S.; Chen, J.; Wang, H.; Yang, Y.; Chunying, L.; et al. Aberrant SIRT6 expression contributes to melanoma growth: Role of the autophagy paradox and IGF-AKT signaling. Autophagy 2017, 14, 518–533. [CrossRef]

322. Bae, J.S.; Park, S.-H.; Jamiyandorj, U.; Kim, K.M.; Noh, S.I.; Kim, J.R.; Park, H.J.; Kwon, K.S.; Jung, S.H.; Park, H.S.; et al. CK2α/CSNK2A1 Phosphorylates SIRT6 and Is Involved in the Progression of Breast Carcinoma and Predicts Shorter Survival of Diagnosed Patients. Ant. J. Pathol. 2016, 186, 3297–3315. [CrossRef] [PubMed]

323. Qu, N.; Hu, J.; Zhang, T.; Sun, G.; Shi, R.-L.; Ji, Q.; Liu, L. SIRT6 is upregulated and associated with cancer aggressiveness in papillary thyroid cancer via BRAF/ERK/Mcl-1 pathway. Int. J. Oncol. 2017, 50, 1683–1692. [CrossRef]

324. Bae, J.S.; Park, S.-H.; Jamiyandorj, U.; Kim, K.M.; Noh, S.I.; Kim, J.R.; Park, H.J.; Kwon, K.S.; Jung, S.H.; Park, H.S.; et al. CK2α/CSNK2A1 Phosphorylates SIRT6 and Is Involved in the Progression of Breast Carcinoma and Predicts Shorter Survival of Diagnosed Patients. Ant. J. Pathol. 2016, 186, 3297–3315. [CrossRef] [PubMed]

325. Guan, D.; Lim, J.H.; Peng, L.; Liu, Y.; Lam, M.; Seto, E.; Kao, H.-Y. Decaycetylation of the tumor suppressor protein PML regulates hydrogen peroxide-induced cell death. Cell Death Dis. 2014, 5, e1340. [CrossRef] [PubMed]

326. Min, L.; Ji, Y.; Bakiri, L.; Qiu, Z.; Cen, J.; Chen, X.; Chen, L.; Scheuch, H.; Zheng, H.; Qin, L.; et al. Liver cancer initiation is controlled by AP-1 through SIRT6-dependent inhibition of survivin. Nat. Cell Biol. 2012, 14, 1203–1211. [CrossRef] [PubMed]

327. Bhardwaj, A.; Das, S. SIRT6 deacetylates PKM2 to suppress its nuclear localization and oncogenic functions. Proc. Natl. Acad. Sci. USA 2016, 113, E538–E547. [CrossRef] [PubMed]

328. Zhang, Z.-G.; Qin, C.-Y. Sirt6 suppresses hepatocellular carcinoma cell growth via inhibiting the extracellular signal-regulated kinase signaling pathway. Mol. Med. Rep. 2013, 9, 882–888. [CrossRef] [PubMed]

329. Kohli, S.; Bhardwaj, A.; Kumari, R.; Das, S. SIRT6 Is a Target of Regulation by UBE3A That Contributes to Liver Tumorigenesis in an ANXA2-Dependent Manner. Cancer Res. 2017, 78, 645. [CrossRef]

330. Sebastián, C.; Zwaans, B.M.M.; Silberman, D.M.; Gymrek, M.; Goren, A.; Zhong, L.; Ram, O.; Truelove, J.; Guimaraes, A.R.; Toiber, D.; et al. The Histone Deacetylase SIRT6 Is a Tumor Suppressor that Controls Cancer Metabolism. Cell 2012, 151, 1185–1199. [CrossRef]

331. Lin, Z.; Yang, H.; Tan, C.; Li, J.; Liu, Z.; Quan, Q.; Kong, S.; Ye, J.; Gao, B.; Fang, D. USP10 Antagonizes c-Myc Transcriptional Activation through SIRT6 Stabilization to Suppress Tumor Formation. Cell Rep. 2013, 5, 1639–1649. [CrossRef]

332. Wu, X.; Tian, H.; Xue, L.; Wang, L. SIRT6 abrogation promotes adrenocortical carcinoma through activation of NF-kB signaling. Mol. Cell. Biochem. 2019, 458, 1–10. [CrossRef]
Cancers 2021, 13, 188

330. Feng, J.; Yan, P.-F.; Zhao, H.-Y.; Zhang, F.-C.; Zhao, W.-H.; Feng, M. SIRT6 suppresses glioma cell growth via induction of apoptosis, inhibition of oxidative stress and suppression of JAK2/STAT3 signaling pathway activation. Oncol. Rep. 2015, 35, 1395–1402. [CrossRef]

331. Han, Z.; Liu, L.; Liu, Y.; Li, S. Sirtuin 7 suppresses cell proliferation through inhibition of Twist1 expression in non-small cell lung cancer. Int. J. Clin. Exp. Pathol. 2014, 7, 4774–4781.

332. Zhang, J.; Yin, X.-J.; Xu, C.-J.; Ning, Y.-X.; Chen, M.; Zhang, H.; Chen, S.-F.; Yao, L.-Q. The histone deacetylase SIRT6 inhibits ovarian cancer cell proliferation via down-regulation of Notch 3 expression. Eur. Rev. Med. Pharmacol. Sci. 2015, 19, 818–824. [PubMed]

333. Kugel, S.; Sebastián, C.; Fitamant, J.; Ross, K.N.; Saha, S.K.; Jain, E.; Gladden, A.; Arora, K.S.; Kato, Y.; Rivera, M.N.; et al. SIRT6 Suppresses Pancreatic Cancer through Control of Lin28b. Cell 2016, 165, 1401–1415. [CrossRef] [PubMed]

334. Aljada, A.; Saleh, A.M.; Alkathiri, M.; Shamsa, H.B.; Al-Bawab, A.; Nasr, A. Altered Sirtuin 7 Expression is Associated with Colon Cancer Cells Progression and Synergize with Chemotherapeutic Drugs to Induce Cell Death. Cancer Manag. Res. 2017, 9, 1884–1894. [CrossRef]

335. Choe, M.; Brusgard, J.L.; Chumsri, S.; Bhandary, L.; Zhao, X.F.; Lu, S.; Goloubeva, O.G.; Polster, B.M.; Fiskum, G.; Girnun, G.D.; et al. The RUNX2 Transcription Factor Negatively Regulates SIRT6 Expression to Alter Glucose Metabolism in Breast Cancer Cells. J. Cell. Biochem. 2015, 116, 2210–2226. [CrossRef] [PubMed]

336. Wei, W.; Jing, Z.X.; Ke, Z.; Yi, P. Sirtuin 7 plays an oncogenic role in human osteosarcoma via downregulating CDC4 expression. Am. J. Cancer Res. 2017, 7, 1788–1803. [PubMed]

337. Wang, H.-L.; Lu, R.-Q.; Xie, S.-H.; Zheng, H.; Wen, X.-M.; Gao, X.; Guo, L. SIRT7 Exhibits Oncogenic Potential in Human Ovarian Cancer Cells. Asian Pac. J. Cancer Prev. 2015, 16, 3573–3577. [CrossRef]

338. Aljada, A.; Saleh, A.M.; Alkathiri, M.; Shamsa, H.B.; Al-Bawab, A.; Nasr, A. Altered Sirtuin 7 Expression is Associated with Early-Stage Breast Cancer. Breast Cancer Basic Clin. Res. 2015, 9, 3–8. [CrossRef]

339. Wang, P.; Sang, S. Metabolism and pharmacokinetics of resveratrol and pterostilbene. BioMed. Pharmacother. 2017, 88, 1–5. [CrossRef]

340. Malik, S.; Villanova, L.; Tanaka, S.; Aonuma, M.; Roy, N.; Berber, E.; Pollack, J.R.; Michishita-Kioi, E.; Chua, K.F. SIRT7 inactivation reverses metastatic phenotypes in epithelial and mesenchymal tumors. Sci. Rep. 2015, 5, 9841. [CrossRef]

341. Li, W.; Zhu, D.; Qin, S. SIRT7 suppresses the epithelial-to-mesenchymal transition in oral squamous cell carcinoma metastasis by promoting SMAD4 deacetylation. J. Exp. Clin. Cancer Res. 2018, 37, 148. [CrossRef] [PubMed]

342. Tang, X.; Shi, L.; Xie, N.; Liu, Z.; Qian, M.; Meng, F.; Xu, Q.; Zhou, M.; Cao, X.; Zhu, W.-G.; et al. SIRT7 antagonizes TGF-β signaling and inhibits breast cancer metastasis. Nat. Commun. 2017, 8, 1–14. [CrossRef] [PubMed]

343. Costa-Machado, L.F.; Fernández-Marcos, P.J. The sirtuin family in cancer. Cell Cycle 2019, 18, 2164–2196. [CrossRef] [PubMed]

344. Intagliata, S.; Modica, M.N.; Santagati, L.M.; Montenegro, L. Strategies to Improve Resveratrol Systemic and Topical Bioavailability: An Update. Antioxidants 2019, 8, 244. [CrossRef]

345. Sengides, C.; Chiriá, M.; Silvestro, L.; Pitta, D.; Pittas, A. Bioavailability and safety study of resveratrol 500 mg tablets in healthy male and female volunteers. Exp. Ther. Med. 2016, 11, 164–170. [CrossRef]

346. Gambini, J.; Inglés, M.; Olaso, G.; Lopezgrueso, R.; Bonetcosta, V.; Gimenomallench, L.; Mas-Bargues, C.; Abdelaziz, K.M.; Gomezcabrera, M.C.; Vina, J.; et al. Properties of Resveratrol: In Vitro and in Vivo Studies about Metabolism, Bioavailability, and Biological Effects in Animal Models and Humans. Oxidative Med. Cell. Longev. 2015, 2015, 5, 9787. [CrossRef]

347. Springer, M.; Moco, S. Resveratrol and Its Human Metabolites—Effects on Metabolic Health and Obesity. Nutrients 2019, 11, 143. [CrossRef]

348. Leifer, A.; Barberio, D.M. Direct ingestion method for enhancing production and bioavailability of resveratrol and other phytoalexins in Vitis vinifera. Med. Hypotheses 2016, 86, 1–5. [CrossRef]

349. Tsai, H.-Y.; Ho, C.-T.; Chen, Y.K. Biological actions and molecular effects of resveratrol, pterostilbene, and 3′-hydroxypterostilbene. J. Food Drug Anal. 2017, 25, 134–147. [CrossRef]

350. Draijer, R.; van Dorsten, F.A.; Zebregs, Y.E.; Hollebrands, B.; Peters, S.; Duchateau, G.; Grün, C.H. Impact of Proteins on the Uptake, Distribution, and Excretion of Phytoalexins in the Human Body. Nutrients 2016, 8, 614. [CrossRef]

351. Wang, P.; Sang, S. Metabolism and pharmacokinetics of resveratrol and pterostilbene. BioFactors 2018, 44, 16–25. [CrossRef] [PubMed]

352. Ramirez-Garza, S.L.; Laveriano-Santos, E.P.; Marhuenda-Muñoz, M.; Storniolo, C.E.; Tresserra-Rimbau, A.; Vallverdú-Queralt, A.; Lamuela-Raventós, R.M. Health Effects of Resveratrol: Results from Human Intervention Trials. Nutrients 2018, 10, 1892. [CrossRef] [PubMed]

353. Yang, Y.; Zhang, G.; Li, C.; Wang, S.; Zhu, M.; Wang, J.; Yue, H.; Ma, X.; Zhen, Y.; Shu, X. Metabolic profile and structure-activity relationship of resveratrol and its analogs in human bladder cancer cells. Cancer Manag. Res. 2019, 11, 4631–4642. [CrossRef]

354. Aires, V.; Limagne, E.; Cotte, A.K.; Latruffe, N.; Ghiringhelli, F.; Delmas, D. Resveratrol metabolites inhibit human metastatic colon cancer cells progression and synergize with chemotherapeutic drugs to induce cell death. Mol. Nutr. Food Res. 2013, 57, 1170–1181. [CrossRef] [PubMed]
356. Guthrie, A.R.; Chow, H.-H.S.; Miller, J.A. Effects of resveratrol on drug- and carcinogen-metabolizing enzymes, implications for cancer prevention. *Pharmacol. Res. Perspect.* 2017, 5, e00294. [CrossRef]

357. PanNu, N.; Bhatnagar, A. Resveratrol: From enhanced biosynthesis and bioavailability to multitargeting chronic diseases. *Biomed. Pharmacother.* 2019, 109, 2237–2251. [CrossRef]

358. Patel, K.R.; Brown, V.A.; Jones, D.J.L.; Britton, R.G.; Hemingway, D.; Miller, A.S.; West, K.P.; Booth, T.D.; Perloff, M.; Crowell, J.A.; et al. Clinical Pharmacology of Resveratrol and Its Metabolites in Colorectal Cancer Patients. *Cancer Res.* 2010, 70, 7392–7399. [CrossRef]

359. Lee, S.-J.; Yim, D.-G.; Hur, S.J. Changes in the Content and Bioavailability of Onion Quercetin and Grape Resveratrol during In Vitro Human Digestion. *Foods* 2020, 9, 694. [CrossRef]

360. Brown, V.A.; Patel, K.R.; Viskaduraki, M.; Crowell, J.A.; Perloff, M.; Booth, T.D.; Vasilinin, G.; Sen, A.; Schinas, A.M.; Piccirilli, G.; et al. Repeat Dose Study of the Cancer Chemopreventive Agent Resveratrol in Healthy Volunteers: Safety, Pharmacokinetics, and Effect on the Insulin-like Growth Factor Axis. *Cancer Res.* 2010, 70, 9003–9011. [CrossRef]

361. Almeida, L.; Vaz-Da-Silva, M.; Falcão, A.; Soares, E.; Costa, R.; Loureiro, A.I.; Fernandes-Lopes, C.; Rocha, J.-F.; Nunes, T.; Wright, L.; et al. Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. *Mol. Nutr. Food Res.* 2009, 53, S7–S15. [CrossRef]

362. Vasconcelos, T.; Araújo, F.; Lopes, C.; Loureiro, A.; Das Neves, J.; Marques, S.; Sarmento, B. Multicomponent self-nano emulsifying delivery systems of resveratrol with enhanced pharmacokinetics profile. *Eur. J. Pharm. Sci.* 2019, 137, 105011. [CrossRef]

363. Calvo-Castro, L.A.; Schiborr, C.; David, F.; Ehrt, H.; Voggel, J.; Sus, N.; Behnäm, D.; Bosy-Westphal, A.; Frank, J. The Oral Bioavailability of Trans-Resveratrol from a Grapevine-Shoot Extract in Healthy Humans is Significantly Increased by Micellar Solubilization. *Mol. Nutr. Food Res.* 2018, 62, e170517. [CrossRef] [PubMed]

364. Santos, A.C.; Veiga, F.; Sequeira, J.A.D.; Fortuna, A.; Falcão, A.; Souto, E.B.; Pattekari, P.; Ribeiro, C.F.; Ribeiro, A.J. First-time oral administration of resveratrol-loaded layer-by-layer nanoparticles to rats—A pharmacokinetics study. *Analyst* 2019, 144, 2062–2079. [CrossRef] [PubMed]

365. Yang, C.; Wang, Y.; Xie, Y.; Liu, G.; Lu, Y.; Wu, W.; Chen, L. Oat protein-shellac nanoparticles as a delivery vehicle for resveratrol to improve bioavailability in vitro and in vivo. *Nanomedicine* 2019, 14, 2853–2871. [CrossRef] [PubMed]

366. Peñalva, R.; Morales, J.; González-Navarro, C.J.; Larañeta, E.; Quincoces, G.; Peruelas, I.; Irache, J. (Juan M. Increased Oral Bioavailability of Resveratrol by Its Encapsulation in Casein Nanoparticles. *Int. J. Mol. Sci.* 2018, 19, 2816. [CrossRef] [PubMed]

367. Singh, S.K.; Makadia, V.; Sharma, S.; Rashid, M.; Shahi, S.; Mishra, P.R.; Wahajuddin, M.; Gayen, J.R. Preparation and in-vitro/in-vivo characterization of trans-resveratrol nanocrystals for oral administration. *Drug Deliv. Transl. Res.* 2017, 7, 395–407. [CrossRef] [PubMed]

368. Wu, M.; Zhong, C.; Deng, Y.; Zhang, Q.; Zhang, X.; Zhao, X. Resveratrol loaded glycyrrhizin acid-conjugated human serum albumin nanoparticles for tail vein injection II: Pharmacokinetics, tissue distribution and bioavailability. *Drug Deliv.* 2020, 27, 81–90. [CrossRef] [PubMed]

369. Katekar, R.; Thombre, G.; Riyazuddin, M.; Husain, A.; Rani, H.; Praveena, K.S.; Gayen, J.R. Pharmacokinetics and brain targeting of trans-resveratrol loaded mixed micelles in rats following intravenous administration. *Pharm. Dev. Technol.* 2019, 25, 300–307. [CrossRef]

370. Guo, L.; Peng, Y.; Yao, J.; Sui, L.; Gu, A.; Wang, J. Anticancer Activity and Molecular Mechanism of Resveratrol–Bovine Serum Albumin Nanoparticles on Subcutaneously Implanted Human Primary Ovarian Carcinoma Cells in Nude Mice. *Cancer Biother. Radiopharm.* 2010, 25, 471–477. [CrossRef]

371. Johnson, J.J.; Nihal, M.; Siddiqui, I.A.; Scarlett, C.O.; Bailey, H.H.; Mukhtar, H.; Ahmad, N. Enhancing the bioavailability of resveratrol by combining it with piperine. *Radiopharm. Res. Perspect.* 2017, 5, e00294. [CrossRef] [PubMed]

372. de Santi, C.; Pietrabissa, A.; Spisni, R.; Mosca, F.; Pacifici, G.M. Sulphation of resveratrol, a natural compound present in wine, and its inhibition by natural flavonoids. *Xenobiotica* 2000, 30, 857–866. [CrossRef] [PubMed]

373. Chimento, A.; de Amicis, F.; Sirianni, R.; Sinicropi, M.S.; Puoci, F.; Casaburi, I.; Santoro, C.; Pezzi, V. Progress to Improve Oral Bioavailability and Beneficial Effects of Resveratrol. *Int. J. Mol. Sci.* 2019, 20, 1381. [CrossRef] [PubMed]

374. Salehi, B.; Mishra, A.P.; Nigam, M.; Sener, B.; Kilic, M.; Sharifi-Rad, M.; Fokou, P.V.T.; Martins, N.; Sharifi-Rad, J. Resveratrol: A Double-Edged Sword in Health Benefits. *Biomedicines* 2018, 6, 91. [CrossRef]

375. Berman, A.Y.; Motetchin, R.A.; Wiesenfeld, M.Y.; Holz, M.K. The therapeutic potential of resveratrol: A review of clinical trials. *NPJ Precis. Oncol.* 2017, 1, 1–9. [CrossRef] [PubMed]

376. Chow, H.-H.S.; Garland, L.L.; Hsu, C.-H.; Vining, D.R.; Chew, W.M.; Miller, J.A.; Perloff, M.; Crowell, J.A.; Alberts, D.S. Resveratrol Modulates Drug- and Carcinogenic-Metabolizing Enzymes in a Healthy Volunteer Study. *Cancer Prev. Res.* 2010, 3, 1168–1175. [CrossRef]

377. Zhu, W.; Qin, W.; Zhang, K.; Rottermans, G.E.; Chen, Y.-C.; Kliethermes, B.; Sauter, E.R. Trans-Resveratrol Alters Mammary Promoter Hypermethylation in Women at Increased Risk for Breast Cancer. *Nutr. Cancer* 2012, 64, 393–400. [CrossRef]

378. Chow, H.-H.S.; Garland, L.L.; Heckman-Stoddard, B.M.; Hsu, C.-H.; Butler, V.D.; A Cordova, C.; Chew, W.M.; Cornellison, T.L. A pilot clinical study of resveratrol in postmenopausal women with high body mass index: Effects on systemic sex steroid hormones. *J. Transl. Mol.* 2014, 12, 223. [CrossRef]

379. Klement, R.J.; Fink, M.K. Dietary and pharmacological modification of the insulin/IGF-1 system: Exploiting the full repertoire against cancer. *Oncogene* 2016, 5, e193. [CrossRef]
Cancers 2021, 13, 188

380. Ter-Braak, B.; Siezen, C.L.; Lee, J.S.; Rao, P.; Voorhoeve, C.; Ruppin, E.; van der Laan, J.W.; van de Water, B. Insulin-like growth factor 1 receptor activation promotes mammary gland tumor development by increasing glycolysis and promoting biomass production. *Bras Cancer Res.* 2017, 19, 14. [CrossRef]

381. Banaszewska, B.; Wrotyńska-Barczyńska, J.; Spaczynski, R.Z.; Paweleczk, L.; Dudek, A.J. Effects of Resveratrol on Polycystic Ovary Syndrome: A Double-blind, Randomized, Placebo-controlled Trial. *J. Clin. Endocrinol. Metab.* 2016, 101, 4322–4328. [CrossRef]

382. Mo, Y.; Wang, Y.; Zhang, L.; Yang, L.; Zhou, M.; Li, X.; Li, Y.; Li, G.; Zeng, Z.; Xiong, W.; et al. The role of Wnt signaling pathway in tumor metabolic reprogramming. *J. Cancer* 2019, 10, 3789–3797. [CrossRef] [PubMed]

383. Ashrafizadeh, M.; Ahmadi, Z.; Farkhondeh, T.; Samanghadi, S. Resveratrol downregulates inflammatory pathway activated by lymphotoxin α (TNF-α) in particular chondrocytes: Comparison with TNF-α. *PloS ONE* 2017, 12, e0186993. [CrossRef] [PubMed]

384. Liskova, A.; Koklesova, L.; Samec, M.; Zhai, K.; Buhrmann, C.; Varghese, E.; Abotaleb, M.; Qaradakhi, T.; Zulli, A.; et al. Flavonoids against the Warburg phenotype—Concepts of predictive, preventive and personalised medicine to cut the Gordian knot of cancer cell metabolism. *EPMA J.* 2020, 11, 377–398. [CrossRef]

385. Turner, R.S.; Thomas, R.G.; Craft, S.; van Dyck, C.H.; Mintzer, J.; Reynolds, B.A.; Brewer, J.B.; Rissman, R.A.; Raman, R.; Aisen, P.S.; et al. A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. *Neurology* 2015, 85, 1383–1391. [CrossRef] [PubMed]

386. la Porte, C.J.L.; Voduc, N.; Zhang, G.; Seguin, I.; Tardiff, D.; Singhal, N.; Cameron, D.W. Steady-State Pharmacokinetics and Tolerability of Trans-Resveratrol 2000 mg Twice Daily with Food, Quercetin and Alcohol (Ethanol) in Healthy Human Subjects. *Clin. Pharmacokinet.* 2010, 49, 449–454. [CrossRef]

387. Samec, M.; Liskova, A.; Koklesova, L.; Samuel, S.M.; Zhai, K.; Buhrmann, C.; Varghese, E.; Abotaleb, M.; Qaradakhi, T.; Zulli, A.; et al. Flavonoids against the Warburg phenotype—Concepts of predictive, preventive and personalised medicine to cut the Gordian knot of cancer cell metabolism. *EPMA J.* 2020, 11, 377–398. [CrossRef]

388. Ashrafizadeh, M.; Fekri, H.S.; Ahmadi, Z.; Farkhondeh, T.; Samanghadi, S. Therapeutic and biological activities of berberine: Protective effects in human diseases. *Arch. Pharmacol. Biochem.* 2019, 10, 1–9. [CrossRef]

389. Turner, R.S.; Thomas, R.G.; Craft, S.; van Dyck, C.H.; Mintzer, J.; Reynolds, B.A.; Brewer, J.B.; Rissman, R.A.; Raman, R.; Aisen, P.S.; et al. A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. *Neurology* 2015, 85, 1383–1391. [CrossRef] [PubMed]

390. la Porte, C.J.L.; Voduc, N.; Zhang, G.; Seguin, I.; Tardiff, D.; Singhal, N.; Cameron, D.W. Steady-State Pharmacokinetics and Tolerability of Trans-Resveratrol 2000 mg Twice Daily with Food, Quercetin and Alcohol (Ethanol) in Healthy Human Subjects. *Clin. Pharmacokinet.* 2010, 49, 449–454. [CrossRef]

391. Liskova, A.; Kubatka, P.; Samec, M.; Zhai, K.; Buhrmann, C.; Varghese, E.; Abotaleb, M.; Qaradakhi, T.; Zulli, A.; et al. Flavonoids against the Warburg phenotype—Concepts of predictive, preventive and personalised medicine to cut the Gordian knot of cancer cell metabolism. *EPMA J.* 2020, 11, 377–398. [CrossRef]

392. Shakibaei, M.; Kraehe, P.; Lueders, C.; Shayan, P.; Goel, A. Curcumin potentiates antitumor activity of 5-fluorouracil in a 3D alginate tumor microenvironment of colorectal cancer. *Cancer Stem Cells and Stromal Fibroblasts in the Tumor Microenvironment: Potential Role of Apoptosis Induction in CRC Cells. Biomedicines 2020, 8, 236. [CrossRef]

393. Buhrmann, C.; Yazdi, M.; Popper, B.; Shayan, P.; Goel, A.; Aggarwal, B.B.; Shakibaei, M. Evidence that TNF-β induces proliferation in colorectal cancer cells and resveratrol can down-modulate it. *Exp. Biol. Med.* 2019, 244, 1–12. [CrossRef]

394. Buhrmann, C.; Kraehe, P.; Lueders, C.; Shayan, P.; Goel, A.; Shakibaei, M. Curcumin Suppresses Crossstalk between Colon Cancer Stem Cells and Stromal Fibroblasts in the Tumor Microenvironment: Potential Role of EMT. *PloS ONE* 2014, 9, e107514. [CrossRef]

395. Shakibaei, M.; Buhrmann, C.; Kraehe, P.; Shayan, P.; Lueders, C.; Goel, A. Curcumin Chemosensitizes 5-Fluorouracil Resistant MMR-Deficient Human Colon Cancer Cells in High Density Cultures. *PloS ONE* 2014, 9, e83397. [CrossRef]

396. Shakibaei, M.; Kraehe, P.; Popper, B.; Shayan, P.; Goel, A.; Buhrmann, C. Curcumin potentiates antitumor activity of 5-fluorouracil in a 3D alginate tumor microenvironment of colorectal cancer. *BMCCancer 2015, 15, 250. [CrossRef]

397. Shakibaei, M.; Mobasheri, A.; Lueders, C.; Busch, F.; Shayan, P.; Goel, A. Curcumin Enhances the Effect of Chemotherapy against Colorectal Cancer Cells by Inhibition of NF-κB and Src Protein Kinase Signaling Pathways. *PloS ONE* 2013, 8, e57218. [CrossRef]

398. Toden, S.; Okugawa, Y.; Jascut, T.; Wodarz, D.; Komarova, N.L.; Buhrmann, C.; Shakibaei, M.; Boland, C.R.; Goel, A. Curcumin mediates chemosensitization to 5-fluorouracil through miRNA-induced suppression of epithelial-to-mesenchymal transition in chemoresistant colorectal cancer. *Carcinogenesis 2015, 36, 355–367. [CrossRef] [PubMed]